

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | |
|--|----------------------------|---|---|
| (51) International Patent Classification ⁶ : C07D 213/30, A61K 31/19, 31/41, 31/44, C07D 333/16, 317/54, C07C 59/70 | | A1 | (11) International Publication Number: WO 96/22978 |
| | | | (43) International Publication Date: 1 August 1996 (01.08.96) |
| (21) International Application Number: PCT/GB96/00120 | | | |
| (22) International Filing Date: 22 January 1996 (22.01.96) | | | |
| (30) Priority Data: | | | |
| 9501635.8 | 27 January 1995 (27.01.95) | GB | |
| 9504061.4 | 1 March 1995 (01.03.95) | GB | |
| 9509604.6 | 11 May 1995 (11.05.95) | GB | |
| (71) Applicant (for all designated States except US): RHONE-POULENC RORER LIMITED [GB/GB]; RPR House, 52 St. Leonards Road, Eastbourne, East Sussex BN21 3YG (GB). | | | |
| (72) Inventors; and | | | |
| (75) Inventors/Applicants (for US only): PORTER, Barry [GB/GB]; Rhone-Poulenc Rorer Limited, Rainham Road South, Dagenham, Essex RM10 7XS (GB). SMITH, Christopher [GB/GB]; Rhone-Poulenc Rorer Limited, Rainham Road South, Dagenham, Essex RM10 7XS (GB). WALSH, Roger, John, Aitchison [GB/GB]; Rhone-Poulenc Rorer Limited, Rainham Road South, Dagenham, Essex RM10 7XS (GB). MAJID, Tahir, Nadeem [GB/GB]; Rhone-Poulenc Rorer Limited, Rainham Road South, Dagenham, Essex RM10 7XS (GB). MCCARTHY, Clive [GB/GB]; Rhone-Poulenc Rorer Limited, Rainham Road | | | |
| | | (74) Agent: CAFFIN, Lee; Rhone-Poulenc Rorer Limited, Patent Dept., Rainham Road South, Dagenham, Essex RM10 7XS (GB). | |
| | | (81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AZ, BY, KG, KZ, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). | |
| | | Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments. | |

(54) Title: SUBSTITUTED PHENYL COMPOUNDS AS ENDOTHELIN ANTAGONISTS



(57) Abstract

Compounds of formula (I) are described, wherein: R¹ is CN, CH₂CN, CH=CHCN, CHO, or CH=CHCO₂H; R² is aryl lower alkoxy, heteroaryl lower alkoxy, aryl lower alkylthio or heteroaryl lower alkylthio in which each of the aryl and heteroaryl moieties is optionally substituted; R³ is halogen; R⁴ is optionally substituted aryl or optionally substituted heteroaryl; R⁵ is carboxy or an acid isostere; X is oxygen or sulphur; and n is zero or 1; and their N-oxides and prodrugs, and pharmaceutically acceptable salts thereof. The compounds have endothelin antagonist activity and are useful as pharmaceuticals.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|--------------------------|----|--|----|--------------------------|
| AM | Armenia | GB | United Kingdom | MW | Malawi |
| AT | Austria | GE | Georgia | MX | Mexico |
| AU | Australia | GN | Guinea | NE | Niger |
| BB | Barbados | GR | Greece | NL | Netherlands |
| BE | Belgium | HU | Hungary | NO | Norway |
| BF | Burkina Faso | IE | Ireland | NZ | New Zealand |
| BG | Bulgaria | IT | Italy | PL | Poland |
| BJ | Benin | JP | Japan | PT | Portugal |
| BR | Brazil | KE | Kenya | RO | Romania |
| BY | Belarus | KG | Kyrgyzstan | RU | Russian Federation |
| CA | Canada | KP | Democratic People's Republic of Korea | SD | Sudan |
| CF | Central African Republic | KR | Republic of Korea | SE | Sweden |
| CG | Congo | KZ | Kazakhstan | SG | Singapore |
| CH | Switzerland | LI | Liechtenstein | SI | Slovenia |
| CI | Côte d'Ivoire | LK | Sri Lanka | SK | Slovakia |
| CM | Cameroon | LR | Liberia | SN | Senegal |
| CN | China | LT | Lithuania | SZ | Swaziland |
| CS | Czechoslovakia | LU | Luxembourg | TD | Chad |
| CZ | Czech Republic | LV | Latvia | TG | Togo |
| DE | Germany | MC | Monaco | TJ | Tajikistan |
| DK | Denmark | MD | Republic of Moldova | TT | Trinidad and Tobago |
| EE | Estonia | MG | Madagascar | UA | Ukraine |
| ES | Spain | ML | Mali | UG | Uganda |
| FI | Finland | MN | Mongolia | US | United States of America |
| FR | France | MR | Mauritania | UZ | Uzbekistan |
| GA | Gabon | | | VN | Viet Nam |

SUBSTITUTED PHENYL COMPOUNDS AS ENDOTHELIN ANTAGONISTS

5 This invention is directed to substituted phenyl compounds, their preparation, pharmaceutical compositions containing these compounds, and their pharmaceutical use in the treatment of disease states
10 associated with endothelin peptides.

Endothelins are a family of peptides, mainly synthesized and released by endothelial cells. The term endothelin (ET) refers to a family of homologous
15 21-amino acid peptides found in three distinct isoforms: ET-1, ET-2 and ET-3, and in the present specification the term "endothelin" is intended to refer to any or all of the isoforms of endothelin. Each endothelin isopeptide is encoded by a distinct
20 gene with a distinct chromosomal locus for each human gene.

Receptor subtypes ET_A and ET_B specific for endothelin have been identified (H. Arai, et al., Nature, 348,
25 730 (1990) and T. Sakurai et al., Nature, 348, 732 (1990)). ET-1 and ET-2 bind more potently than ET-3 to ET_A, and stimulation of this receptor subtype promotes vasoconstriction. ET-1, ET-2 and ET-3 bind with equal affinity to ET_B receptors, and stimulation of this
30 receptor subtype can evoke vasodilation or promote vasoconstriction.

Thus, endothelin is an important potent vasoconstrictor producing long-lasting effects in arteries and veins.
35 Consequently, endothelin causes profound actions on the cardiovascular system in particular the coronary,

renal, mesenteric and cerebral circulation. Other biological activities by endothelin are also observed.

Intravenous infusion of ET-1 to rats causes a transient
5 hypotensive effect, followed by a sustained increase in blood pressure. Even low doses of endothelin, which alone are without pressor actions, potentiate the effects of other vasoconstrictor agents. Significantly elevated plasma immunoreactive ET-1 levels have been
10 reported in patients with disorders such as myocardial infarction including acute myocardial infarction, coronary heart disease, unstable angina including vasospastic angina, preeclampsia, essential and pulmonary hypertension and congestive heart failure.

15 Renal blood vessels are particularly sensitive to the vasoconstrictor effect of ET. It produces a marked reduction in renal blood flow accompanied by reductions in glomerular filtration rate, urine volume and urinary
20 sodium and potassium excretion. Endothelin is also mitogenic for mesangial cells. Thus, endothelin has a role in a number of renal disorders such as acute renal insufficiency and chronic renal insufficiency and cyclosporin induced nephrotoxicity. Furthermore,
25 erythropoietin causes endothelin release and that release plays a role in renal complications and hypertension occurring as side effects in dialysis patients.

30 Endothelin induces a proliferative response in vascular smooth muscle cells and this, combined with observations of elevated circulating levels of ET-1 in atherosclerosis, indicates that endothelin contributes to the pathogenesis of this and related diseases.

35 Levels of endothelin are also elevated after angioplasty and is implicated in the high level of restenosis after percutaneous transluminal angioplasty.

The cerebral vasculature is very sensitive to the pressor actions of the endothelins. A single intrathecal injection of ET-1 in dogs leads to a prolonged constriction of the basilar artery. Hypoxia and ischaemia are potent stimuli for increased release of endothelin by endothelial cells, while the secretion of endogenous vasodilators such as PGI₂ and endothelial derived relaxant factor are reduced. Therefore, endothelin plays an important role in cerebral ischaemia such as stroke and subarachnoid hemorrhage.

Endothelin is a potent contractor of isolated airway tissue including human bronchus. In addition, endothelin has been shown to induce eicosanoid release, possess mitogenic properties for airway smooth muscle and has pronounced inflammatory actions. All of these actions confirm an important role for endothelin in pulmonary pathophysiology and in asthma and related conditions.

Endothelin levels are elevated during septic shock and other endotoxin induced conditions such as disseminated intravascular coagulation, migraine, gastrointestinal disorders such as ulceration and irritable bowel syndrome, Raynauds disease and haemangioendothelioma.

Normal bone remodelling involves the coupling of osteoclast and osteoblast functions, an imbalance of these events leading to pathophysiological bone loss. Both cell types produce endothelin and possess endothelin receptors. Antagonists of selected actions of endothelin would therefore be useful in the treatment of clinical conditions of bone loss, such as osteoporosis.

Endothelin-1 is produced in the human prostate and endothelin receptors have been identified in this

tissue. Since endothelin is a paracrine contractile and proliferative factor in the prostate gland, a role is indicated for endothelin in benign prostatic hyperplasia.

5

Endothelin is produced by tumour cells and in light of its mitogenic properties endothelin receptor antagonists would be useful adjuncts in cancer chemotherapy.


10

The further actions of endothelin on neurotransmitter release are also observed, indicating a role in certain disorders of the central nervous system.

15

We have now found a novel group of compounds which act as endothelin antagonists and are therefore of use in therapy, more particularly for the treatment of a disease state associated with a physiologically detrimental excess of endothelin or a disease state associated with pathological conditions that are modulated by inhibiting endothelin. Thus, according to a first aspect of the present invention, we provide a compound of formula (I):

25



wherein

R^1 is CN, CH_2CN , $CH=CHCN$, CHO, or $CH=CHCO_2H$;

30

R^2 is aryl lower alkoxy, heteroaryl lower alkoxy, aryl lower alkylthio or heteroaryl lower alkylthio in

which each of the aryl and heteroaryl moieties is optionally substituted;

R³ is halogen;

5 R⁴ is optionally substituted aryl or optionally substituted heteroaryl;

R⁵ is carboxy or an acid isostere;

X is oxygen or sulphur; and

n is zero or 1; and their N-oxides and prodrugs, and pharmaceutically acceptable salts thereof.

10

As used above, and throughout the description of the invention, the following terms in parentheses, unless otherwise indicated, shall be understood to have the following meanings:

15

"Acid isostere" means a group which is significantly ionised at physiological pH. Examples of suitable acid isosteres include sulpho, phosphono, alkylsulphonylcarbamoyl, tetrazolyl, arylsulphonylcarbamoyl, heteroarylsulphonylcarbamoyl or N-methoxycarbamoyl.

20

"Alkoxy" means an alkyl-O- group in which the alkyl group is as described herein. Preferred alkoxy groups are lower alkoxy groups having 1 to about 3 carbon atoms. Exemplary alkoxy groups include methoxy, ethoxy and n-propoxy.

25

"Alkyl" means an aliphatic hydrocarbon group which may be straight or branched having about 1 to about 6 carbon atoms in the chain. Preferred alkyl groups have 1 to about 4 carbon atoms in the chain, especially 1 to about 2 carbon atoms. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl are attached to a linear alkyl chain. "Lower alkyl" means about 1 to about 4 carbon atoms in the chain which may be straight or branched. Exemplary alkyl groups

30

35

include methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl and n-pentyl.

"Aryl" means aromatic carbocyclic radical containing about 6 to about 10 carbon atoms. Exemplary aryl include phenyl or naphthyl, or phenyl or naphthyl substituted with one or more aryl group substituents which may be the same or different, where "aryl group substituent" includes alkyl, preferably lower alkyl, halogen for example chlorine, bromine or fluorine, CF₃, amino, nitro, cyano, alkoxy, preferably lower alkoxy and hydroxy, where alkoxy and alkyl are as defined herein.

"Aryl lower alkoxy" means aryl-lower alkyl-O- in which the aryl and lower alkyl are as previously described.

"Aryl lower alkylthio" means aryl-lower alkyl-S- in which the aryl and lower alkyl are as previously described.

"Halogen" means fluorine, chlorine, bromine or iodine.

"Heteroaryl" means about a 5- to about a 10- membered aromatic monocyclic or multicyclic hydrocarbon ring system in which one or more of the carbon atoms in the ring system is/are element(s) other than carbon, for example nitrogen, oxygen or sulfur. The "heteroaryl" may also be substituted by one or more aryl group substituents. Exemplary heteroaryl groups include pyridazinyl, pyrazolyl, 1,3-benzodioxolyl, 1,3-benzoxazolyl, furanyl, thienyl, pyridyl, pyrimidinyl, isoxazolyl, thiazolyl, isothiazolyl, quinolinyl, indolyl, isoquinolinyl, oxazolyl and 1,2,4-oxadiazolyl. Preferred heteroaryl groups include (2-, 3- or 4-)pyridyl, 4-isothiazolyl, 1,3-benzodioxol-5-yl, pyridazin-4-yl and 3-thienyl.

"Heteroaryl lower alkoxy" means heteroaryl-lower alkyl-O- in which the heteroaryl and lower alkyl are as previously described.

5

"Heteroaryl lower alkylthio" means heteroaryl-lower alkyl-S- in which the heteroaryl and lower alkyl are as previously described.

10 "Patient" includes both human and other mammals.

"Pharmaceutically acceptable salt" means a salt form of the parent compound of formula I which is relatively innocuous to a patient when used in therapeutic doses so that the beneficial pharmaceutical properties of the parent compound of formula I are not vitiated by side-effects ascribable to a counter ion of that salt form. Pharmaceutically acceptable salt also includes a zwitterion or internal salt of the compound of formula (I).

20

"Prodrug" means a compound, for example an ester, which is convertible in vivo by metabolic means (e.g. by hydrolysis) to a compound of formula I.

25

The compounds of formula (I) and N-oxides and prodrugs thereof are useful in the form of the free base or acid or in the form of a pharmaceutically acceptable salt thereof. All forms are within the scope of the invention and references herein to a compound of the present invention includes a compound of formula (I) or an N-oxide or prodrug thereof together with a pharmaceutically acceptable salt of such a compound.

30

35 Where a compound of the present invention is substituted with a basic moiety, acid addition salts are formed and are simply a more convenient form for

use; and in practice, use of the salt form inherently amounts to use of the free base form. The acids which can be used to prepare the acid addition salts include preferably those which produce, when combined with the free base, pharmaceutically acceptable salts, that is, salts whose anions are non-toxic to the patient in pharmaceutical doses of the salts, so that the beneficial inhibitory effects on endothelin inherent in the free base are not vitiated by side effects ascribable to the anions. Although pharmaceutically acceptable salts of said basic compounds are preferred, all acid addition salts are useful as sources of the free base form even if the particular salt, per se, is desired only as an intermediate product as, for example, when the salt is formed only for purposes of purification, and identification, or when it is used as intermediate in preparing a pharmaceutically acceptable salt by ion exchange procedures.

Pharmaceutically acceptable salts within the scope of the invention include those derived from the following acids: mineral acids such as hydrochloric acid, sulfuric acid, phosphoric acid and sulfamic acid; and organic acids such as acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamic acid, quinic acid, and the like. The corresponding acid addition salts comprise the following: hydrohalides, such as hydrochloride and hydrobromide, sulfate, phosphate, nitrate, sulfamate, acetate, citrate, lactate, tartarate, malonate, oxalate, salicylate, propionate, succinate, fumarate, maleate, methylene-bis- β -hydroxynaphthoates, gentisates, mesylates, isothionates and di-p-toluoyltartrates, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, cyclohexylsulfamate and quinate, respectively.

Where the compound of the invention is substituted with an acidic moiety, base addition salts may be formed and are simply a more convenient form for use; and in
5 practice, use of the salt form inherently amounts to use of the free acid form. The bases which can be used to prepare the base addition salts include preferably those which produce, when combined with the free acid, pharmaceutically acceptable salts, that is, salts whose
10 cations are non-toxic to the animal organism in pharmaceutical doses of the salts, so that the beneficial inhibitory effects on endothelin inherent in the free acid are not vitiated by side effects ascribable to the cations.

15 Pharmaceutically acceptable salts, including for example alkali and alkaline earth metal salts, within the scope of the invention include those derived from the following bases: sodium hydride, sodium hydroxide,
20 potassium hydroxide, calcium hydroxide, aluminum hydroxide, lithium hydroxide, magnesium hydroxide, zinc hydroxide, ammonia, ethylenediamine, N-methyl-glucamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylenediamine, chloroprocaine,
25 diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)aminomethane, tetramethylammonium hydroxide, and the like.

30 It will be apparent to those skilled in the art that certain compounds of formula (I) can exhibit isomerism, for example geometrical isomerism and optical isomerism. Geometrical isomers include the cis and trans forms of compounds of the invention having an
35 alkenyl moiety. Optical isomers contain asymmetric centers. These asymmetric centers may independently be in either the R or S configuration. All isomers within

formula (I), and their mixtures, are within the scope of the invention.

Such isomers can be separated from their mixtures, by
5 the application or adaptation of known methods, for
example chromatographic techniques such as chiral
chromatography and resolution via chiral amine salts
(e.g. α -methylbenzylamine or ephedrine salts), or they
are separately prepared from the appropriate isomers of
10 their intermediates, for example by the application or
adaptation of methods described herein.

It will be appreciated that within formula (I) above
the groups R^1 , R^2 and R^3 may be attached at any
15 available position on the benzene ring. R^1 may
preferably be attached ortho to the group $-X-CHR^4R^5$
(i.e. the ring 2-position). R^3 may preferably be
attached at the ring 3-position. R^2 may preferably be
attached at the ring 5-position (i.e. para to the
20 preferred R^1 position).

Particular and preferred compounds within formula (I)
include compounds in which the individual moieties R^1
to R^5 , X and n independently have the following
25 meanings:

R^1 may particularly represent CN.

R^2 is preferably heteroaryl lower alkoxy, more
30 preferably heteroarylmethoxy. Exemplary
heteroarylmethoxy groups include pyridylmethoxy (e.g.
3-pyridylmethoxy or especially 4-pyridylmethoxy),
pyridazinylmethoxy (e.g. pyridazin-4-ylmethoxy),
thienylmethoxy (e.g. 3-thienylmethoxy),
35 isothiazolylmethoxy (e.g. 4-isothiazolylmethoxy) and

1,3-benzodioxolylmethoxy (e.g. 1,3-benzodioxol-5-ylmethoxy).

When R^3 is present the halogen substituent may preferably be fluorine.


R^4 is preferably optionally substituted aryl; more preferably phenyl, or especially phenyl substituted at the ortho position relative to the attachment of the phenyl group to the rest of the molecule and optionally further substituted. Preferred phenyl group substituents include one or more (e.g. 1, 2 or 3) substituents selected from lower alkyl (e.g. methyl), halogen (e.g. chlorine or bromine), CN, lower alkoxy (e.g. methoxy) and CF_3 .

R^5 may particularly represent carboxy.

X may particularly represent oxygen.

It is to be understood that the present invention is intended to cover all combinations of particular and preferred groupings as defined herein.

A particular group of compounds of the present invention are compounds of formula (Ia)




wherein R^1 , R^2 , R^3 , R^4 , R^5 , n and X are as defined previously, and their N-oxides and prodrugs, and pharmaceutically acceptable salts thereof.

- 5 Compounds of formula (Ia) in which R^1 represents CN are generally preferred.

- Compounds of formula (Ia) in which R^2 represents heteroaryl lower alkoxy, more particularly a
10 heteroarylmethoxy group such as pyridylmethoxy (e.g. 3-pyridylmethoxy or especially 4-pyridylmethoxy), pyridazinylmethoxy (e.g. pyridazin-4-ylmethoxy), thienylmethoxy (e.g. 3-thienylmethoxy), isothiazolylmethoxy (e.g. 4-isothiazolylmethoxy) and
15 1,3-benzodioxolylmethoxy (e.g. 1,3-benzodioxol-5-ylmethoxy), are also preferred.

- Compounds of formula (Ia) in which $-X-CHR^4R^5$ represents $-O-CHR^4R^5$, more particularly where R^4 is optionally
20 substituted aryl and R^5 is carboxy, are also preferred. Within $-O-CHR^4R^5$, R^4 is preferably phenyl substituted in the ortho position relative to the attachment of the phenyl group to the rest of the R^4 moiety by a lower alkyl (e.g. methyl), CF_3 or chlorine
25 substituent and is optionally further substituted by one or more halogen, lower alkyl, CN or lower alkoxy groups.

- A preferred group of compounds of the present invention
30 are compounds of formula (Ib)



(Ib)

wherein R^2 , R^3 , R^4 and n are as defined previously, and their N-oxides and prodrugs, and pharmaceutically acceptable salts thereof.

5

Particularly preferred are compounds of formula (Ib) wherein R^2 is heteroarylmethoxy and R^4 is optionally substituted aryl (e.g. phenyl substituted in the ortho position by lower alkyl such as methyl, CF_3 or chlorine, and is optionally further substituted by one or more, e.g. 1, 2 or 3, substituents selected from halogen, lower alkyl, CN, and lower alkoxy).

10

Particular compounds of the invention are those wherein the chiral centre associated with the carbon atom α to the moiety X within the group $-\text{X}-\text{CHR}^4\text{R}^5$, or the carbon atom α to the oxygen atom within the group $-\text{O}-\text{CHR}^4\text{CO}_2\text{H}$, has the (S) configuration.

15

Within (Ia) and (Ib), when present R^3 particularly represents a fluorine atom.

20

Compounds of formula (Ib) wherein R^2 is pyridylmethoxy (e.g. 3-pyridylmethoxy or especially 4-pyridylmethoxy), pyridazinylmethoxy (e.g. pyridazin-4-ylmethoxy), thienylmethoxy (e.g. 3-thienylmethoxy), isothiazolylmethoxy (e.g. 4-isothiazolylmethoxy) and 1,3-benzodioxolylmethoxy (e.g. 1,3-benzodioxol-5-ylmethoxy) are particularly preferred.

25

It will be appreciated that the terminology describing some of the isomers of compounds claimed herein, and prepared hereinafter, has been modified from that used in the UK priority applications GB9504061.4 and GB9509604.6 [where individually prepared enantiomers were differentiated as dextrorotatory (prefix +) according to the direction in which, under specified conditions, they rotated the plane of polarised light], following an X-ray determination of the absolute stereochemistry associated with the chiral centre of the carbon atom α to the oxygen atom within the group -O-CH(2-methylphenyl)CO₂H of the Reference Example described as (S)-[5-(1,3-benzodioxol-5-ylmethoxy)-2-cyanophenoxy]-(2-methylphenyl)acetic acid, (-) ephedrine salt.

Particular compounds for use according to the invention are selected from the following:

- (RS)-(2-chlorophenyl)-[2-cyano-5-(4-pyridylmethoxy)-phenoxy]acetic acid;
- (RS)-[2-cyano-5-(3-thienylmethoxy)phenoxy]-phenylacetic acid;
- (RS)-(2-chlorophenyl)-[2-cyano-5-(3-thienylmethoxy)-phenoxy]acetic acid;
- (RS)-[5-(1,3-benzodioxol-5-ylmethoxy)-2-cyanophenoxy]-phenylacetic acid;
- (RS)-[5-(1,3-benzodioxol-5-ylmethoxy)-2-cyanophenoxy]-(2-trifluoromethylphenyl)acetic acid;
- (RS)-[2-cyano-5-(3-thienylmethoxy)phenoxy]-(2-methylphenyl)acetic acid;
- (RS)-[5-(1,3-benzodioxol-5-ylmethoxy)-2-cyanophenoxy]-(2-chlorophenyl)acetic acid;
- (RS)-(2-bromophenyl)-[2-cyano-5-(3-thienylmethoxy)-phenoxy]acetic acid;

- (RS)-(3-chlorophenyl)-[2-cyano-5-(3-thienylmethoxy)-phenoxy]acetic acid;
- (R)-(2-chlorophenyl)-[2-cyano-5-(3-thienylmethoxy)-phenoxy]acetic acid;
- 5 (S)-(2-chlorophenyl)-[2-cyano-5-(3-thienylmethoxy)-phenoxy]acetic acid;
- (RS)-[2-cyano-5-(4-pyridylmethoxy)phenoxy]phenylacetic acid;
- (RS)-[2-cyano-5-(3-thienylmethoxy)phenoxy]-(2-fluorophenyl)acetic acid;
- 10 (RS)-[2-cyano-5-(4-pyridylmethoxy)phenoxy]-(2-methylphenyl)acetic acid;
- (RS)-[2-cyano-5-(3-thienylmethoxy)phenoxy]-(2-trifluoromethylphenyl)acetic acid;
- 15 (RS)-(2-bromophenyl)-[2-cyano-5-(4-pyridylmethoxy)-phenoxy]acetic acid;
- (RS)-[2-cyano-5-(4-pyridylmethoxy)phenoxy]-(2-trifluoromethylphenyl)acetic acid;
- (S)-[2-cyano-5-(4-pyridylmethoxy)phenoxy]-(2-methylphenyl)acetic acid;
- 20 (RS)-(2-chlorophenyl)-[2-cyano-5-(pyridazin-4-ylmethoxy)phenoxy]acetic acid;
- (RS)-[5-(1,3-benzodioxol-5-ylmethoxy)-2-cyanophenoxy]-(2-methylphenyl)acetic acid;
- 25 (RS)-(2-chlorophenyl)-[2-cyano-5-(isothiazol-4-ylmethoxy)phenoxy]acetic acid;
- (RS)-[2-cyano-5-(3-pyridylmethoxy)phenoxy]phenylacetic acid;
- (RS)-[2-formyl-5-(3-thienylmethoxy)phenoxy]phenylacetic acid;
- 30 (RS)-N-[[2-cyano-5-(3-thienylmethoxy)phenoxy]phenylacetyl]-4-isopropylbenzenesulphonamide;
- (RS)-[2-cyano-5-(4-pyridylmethoxy)phenoxy]-(2-methylphenyl)acetic acid, acetoxymethyl ester;
- 35 (RS)-(2-chlorophenyl)-[2-cyano-3-fluoro-5-(3-thienylmethoxy)phenoxy]acetic acid;

- (RS)-[5-(benzoxazol-6-ylmethoxy)-2-cyanophenoxy]-(2-chlorophenyl)acetic acid;
- (RS)-[2-cyano-5-(4-pyridylmethoxy)phenoxy]-[2-(3-methylthienyl)acetic acid;
- 5 (RS)-[(2-cyano-5-(thiazol-5-ylmethoxy)phenoxy]-(2-methylphenyl)acetic acid;
- (RS)-(2-chlorophenyl)-[2-cyano-3-fluoro-5-(4-pyridylmethoxy)phenoxy]acetic acid;
- (RS)-2-[(2-chlorophenyl)-(1H-tetrazol-5-yl)methoxy]-4-
- 10 (4-pyridylmethoxy)benzonitrile;
- (RS)-[3-chloro-2-cyano-5-(4-pyridylmethoxy)phenoxy]-(2-chlorophenyl)acetic acid;
- (RS)-[5-(benzoxazol-6-ylmethoxy)-2-cyanophenoxy]-(2-methylphenyl)acetic acid;
- 15 (S)-[5-(1,3-benzodioxol-5-ylmethoxy)-2-cyanophenoxy]-(2-methylphenyl)acetic acid;
- (S)-[5-(1,3-benzodioxol-5-ylmethoxy)-2-cyano-3-fluorophenoxy]-(2-methylphenyl)acetic acid;
- (RS)-[2-cyano-5-(4-(3-fluoropyridyl)methoxy)phenoxy]-
- 20 (2-methylphenyl)acetic acid;
- (RS)-2-[(2-methylphenyl)-(1H-tetrazol-5-yl)methoxy]-4-(4-pyridylmethoxy)benzonitrile;
- (RS)-4-(1,3-benzodioxol-5-ylmethoxy)-2-[(2-methylphenyl)-(1H-tetrazol-5-yl)methoxy]benzonitrile;
- 25 (RS)-[2-cyano-3-fluoro-5-(4-pyridylmethoxy)phenoxy]-(2-methylphenyl)acetic acid;
- (RS)-[5-(benzoxazol-6-ylmethoxy)-2-cyano-3-fluorophenoxy]-(2-methylphenyl)acetic acid;
- (RS)-[5-(1,3-benzodioxol-5-ylmethoxy)-2-cyano-3-
- 30 fluorophenoxy]-(2-methylphenyl)acetic acid;
- (RS)-[5-(benzoxazol-5-yl)methoxy-2-cyanophenoxy]-(2-methylphenyl)acetic acid;
- (RS)-(5-benzyloxy-2-cyanophenoxy)-(2-methylphenyl)-acetic acid;
- 35 (RS)-[2-cyano-5-(furan-3-ylmethoxy)phenoxy]-(2-methylphenyl)acetic acid;

(RS)-N-methoxy-[2-cyano-5-(3-thienylmethoxy)phenoxy]-(2-methylphenyl)acetamide; and solvates (e.g. hydrates); and pharmaceutically acceptable salts thereof.

5

Particularly preferred compounds of the invention include:

- 10 (RS)-(2-chlorophenyl)-[2-cyano-5-(4-pyridylmethoxy)-phenoxy]acetic acid;
(S)-[5-(1,3-benzodioxol-5-ylmethoxy)-2-cyanophenoxy]-(2-methylphenyl)acetic acid;
(RS)-[5-(1,3-benzodioxol-5-ylmethoxy)-2-cyanophenoxy]-(2-methylphenyl)acetic acid;
15 (RS)-[2-cyano-5-(4-pyridylmethoxy)phenoxy]-(2-methylphenyl)acetic acid;
(S)-[2-cyano-5-(4-pyridylmethoxy)phenoxy]-(2-methylphenyl)acetic acid;
(RS)-[5-(1,3-benzodioxol-5-ylmethoxy)-2-cyano-3-
20 fluorophenoxy]-(2-methylphenyl)acetic acid;
(S)-[5-(1,3-benzodioxol-5-ylmethoxy)-2-cyano-3-fluorophenoxy]-(2-methylphenyl)acetic acid; and solvates (e.g. hydrates); and pharmaceutically acceptable salts thereof.

25

An especially preferred compound of the invention is :

- (S)-[5-(1,3-benzodioxol-5-ylmethoxy)-2-cyanophenoxy]-(2-methylphenyl)acetic acid; and solvates (e.g.
30 hydrates); and pharmaceutically acceptable salts thereof.

- Compounds of formula (I) and their N-oxides and prodrugs and pharmaceutically acceptable salts thereof
35 (hereinafter referred to as "compounds of the invention") exhibit pharmacological activity and accordingly are of use in therapy. More especially,

they are endothelin inhibitors, in particular endothelin A inhibitors. Compounds of the invention accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients
5 suffering from certain medical disorders.

The present invention thus provides compounds of the invention and compositions containing compounds of the invention for use in the treatment of a patient
10 suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of endothelin. For example, compounds within the present invention are useful for the treatment of diseases and conditions characterized by, or having an etiology
15 involving pathogenic endothelin levels. Examples of disease states and conditions which can be ameliorated by the administration of inhibitors of endothelin such as compounds of the invention include vascular ischaemia, for example cerebrovascular disease
20 including cerebral ischaemia such as stroke and subarachnoid hemorrhage, coronary disorders such as myocardial infarction including acute myocardial infarction, coronary heart disease, angina including unstable and vasospastic angina, preeclampsia,
25 essential and pulmonary hypertension and congestive heart failure, renal disorders such as acute renal insufficiency and chronic renal insufficiency, cyclosporin induced nephrotoxicity, erythropoietin induced renal complications and hypertension,
30 gastrointestinal disorders such as ulceration and irritable bowel syndrome, Crohn's disease, poor peripheral skeletal muscle disorders such as peripheral vascular disease, intermittent claudication and critical limb ischaemia, glaucoma, atherosclerosis and
35 related diseases, hypertension, asthma, pulmonary fibrosis, chronic obstructive pulmonary disease, migraine, endotoxin and haemorrhagic shock, Raynauds

disease, benign prostatic hyperplasia, metastatic prostate cancer, bone loss such as osteoporosis, restenosis after angioplasty, diabetic neuropathies and for the treatment of organ hypofunction, particularly
5 hypofunction caused by surgery on or transplant of organs such as the liver. Compounds of the present invention are also useful as a therapy for promoting wound healing and as adjuncts in the treatment of cancer.

10

According to a further feature of the invention there is provided a method for the treatment of a human or animal patient suffering from, or subject to, conditions which can be ameliorated by the
15 administration of an inhibitor of endothelin, especially ET_A , for example conditions as hereinbefore described, which comprises the administration to the patient of an effective amount of compound of the invention or a composition containing a compound of the
20 invention "Effective amount" is meant to describe an amount of compound of the present invention effective in inhibiting endothelin and thus producing the desired therapeutic effect.

25 The present invention also includes within its scope pharmaceutical formulations which comprise at least one of the compounds of the invention in association with a pharmaceutically acceptable carrier or coating.

In practice compounds of the present invention may
30 generally be administered parenterally, rectally or orally. The compounds of the invention may also be administered topically to treat peripheral vascular diseases.

35 Compositions according to the invention may be prepared according to the customary methods, using one or more pharmaceutically acceptable adjuvants or excipients.

The adjuvants comprise, inter alia, diluents, sterile aqueous media and the various non-toxic organic solvents. The compositions may be presented in the form of tablets, capsules, pills, granules, powders, aqueous solutions or suspensions, injectable solutions, elixirs, creams, ointments or syrups, and can contain one or more agents chosen from the group comprising sweeteners, flavorings, colorings, or stabilizers in order to obtain pharmaceutically acceptable preparations.

The choice of vehicle and the content of active substance in the vehicle are generally determined in accordance with the solubility and chemical properties of the product, the particular mode of administration and the provisions to be observed in pharmaceutical practice. For example, excipients such as lactose, sodium citrate, calcium carbonate, dicalcium phosphate and disintegrating agents such as starch, alginic acids and certain complex silicates combined with lubricants such as magnesium stearate, sodium lauryl sulfate and talc may be used for preparing tablets. To prepare a capsule, it is advantageous to use lactose and high molecular weight polyethylene glycols. When aqueous suspensions, or solutions, are used they can contain emulsifying agents or agents which facilitate suspension, or solubilisation. Diluents such as sucrose, ethanol, polyethylene glycol, propylene glycol, glycerol and chloroform or mixtures thereof may also be used.

For parenteral administration, emulsions, suspensions or solutions of the products according to the invention in vegetable oil, for example sesame oil, groundnut oil or olive oil, or aqueous-organic solutions such as water and propylene glycol, injectable organic esters such as ethyl oleate, as well as sterile aqueous

solutions of the pharmaceutically acceptable salts, are used. The solutions of the salts of the products according to the invention are especially useful for administration by intramuscular or subcutaneous
5 injection. The aqueous solutions, also comprising solutions of the salts in pure distilled water, may be used for intravenous administration with the proviso that their pH is suitably adjusted, that they are judiciously buffered and rendered isotonic with a
10 sufficient quantity of glucose or sodium chloride and that they are sterilized by heating, irradiation or microfiltration.

Suitable compositions for inhalation containing a
15 compound of the invention may be prepared by conventional means. For example, compounds of the invention may be dissolved or suspended in a suitable carrier for use in a nebulizer or a suspension or solution aerosol, or may be absorbed or adsorbed onto a
20 suitable solid carrier for use in a dry powder inhaler.

Solid compositions for rectal administration include suppositories formulated in accordance with known methods and containing at least one compound of the
25 invention

Compositions for topical administration include creams and ointments formulated in accordance with known methods, such as a topical carrier such as Plastibase®
30 (mineral oil gelled with polyethylene) and containing at least one compound of the invention.

The percentage of active ingredient in the compositions of the invention may be varied, it being necessary that
35 it should constitute a proportion such that a suitable dosage shall be obtained. Obviously, several unit dosage forms may be administered at about the same

time. The dose employed will be determined by the physician, and depends upon the desired therapeutic effect, the route of administration and the duration of the treatment, and the condition of the patient. In the adult, the doses are generally from about 0.01 to about 100 mg/kg, preferably about 0.02 to about 50 mg/kg, and more preferably about 0.1 to about 25 mg/kg body weight (or from about 1 to about 5000 mg, preferably from about 5 to about 2000 mg) in single of 2 to 4 divided daily doses. In each particular case, the doses will be determined in accordance with the factors distinctive to the subject to be treated, such as age, weight, general state of health and other characteristics which can influence the efficacy of the medicinal product.

The compounds according to the invention may be administered as frequently as necessary in order to obtain the desired therapeutic effect. Some patients may respond rapidly to a higher or lower dose and may find much weaker maintenance doses adequate. For other patients, it may be necessary to have long-term treatments at the rate of 1 to 4 doses per day, in accordance with the physiological requirements of each particular patient. Generally, the active product may be administered orally 1 to 4 times per day. It goes without saying that, for other patients, it will be necessary to prescribe not more than one or two doses per day.

The compounds of the present invention can also be administered in combination with endothelin converting enzyme inhibitors, angiotensin II receptor antagonists, renin inhibitors, angiotensin converting enzyme inhibitors, α - and β -adrenoceptor agonists and antagonists, diuretics, potassium channel activators, calcium channel antagonists, nitrates, antiarrhythmic

agents, positive inotropic agents, serotonin receptor agonists and antagonists, platelet activating factor antagonists, histamine receptor antagonists, proton pump inhibitors, antithrombotic and thrombolytic agents, lipid lowering agents, antibiotic agents and phosphodiesterase inhibitors. If formulated as a fixed dose, such combination products employ the compounds of the present invention within the dosage range described below and the other pharmaceutically active agent within its approved dosage range. The compounds of the present invention may also be formulated with or useful in conjunction with antifungal and immunosuppressive agents such as amphotericin B, cyclosporins and the like to counteract the hypertension and nephrotoxicity secondary to such compounds. The compounds of the present invention may also be used in conjunction with haemodialysis.

Compounds within the scope of the present invention exhibit marked pharmacological activities according to tests described in the literature and reported in detail in the Examples Section herein, which tests results are believed to correlate to pharmacological activity in humans and other mammals.


Thus, according to a further embodiment, we provide a compound of the invention for use in the treatment of a human or animal patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of endothelin, especially ETA.

In another embodiment we provide the use of a compound of the invention in the manufacture of a medicament for the treatment of a human or animal patient suffering from, or subject to, conditions which can be


ameliorated by the administration of an inhibitor of endothelin, especially ET_A.

Compounds of formula (I) may be prepared by the application or adaptation of known methods, which means methods used heretofore or described in the literature. In the following procedures R¹ to R⁵, X and n are as defined in formula (I) unless otherwise stated.

Thus, according to a first process (A), a compound of formula (I) may be prepared by reacting a compound of formula (II)




with a compound of formula (III).




wherein Y is a leaving group such as a halogen atom or an aryl- or alkyl-sulphonyloxy group (e.g. methane- or p-toluene-sulphonyloxy) and R^{5a} is a protected derivative of R⁵, including carboxylic acid ammonium salts, followed by removal of the protecting group.

25

Compounds of formula (Ib) may thus be prepared by reacting a compound of formula (IIa)



with a compound of formula (IIIa)




5 in which the cation is derived from a classical chiral base (e.g. ephedrine). Particular compounds of formula (Ib) in which the chiral centre associated with the O-CHR⁴CO₂H group has the (S)-configuration are prepared by reacting a compound of formula (IIa) with a compound
 10 of formula (IIIa) in which the cation N⁺H₂R⁶R⁷ is derived from (-)-ephedrine.


The displacement reaction takes place in the presence of a suitable base such as an alkali metal carbonate
 15 (e.g. potassium carbonate, cesium carbonate), an alkali metal alkoxide (e.g. potassium t-butoxide), an alkali metal phosphate (e.g. potassium phosphate) which is a particularly suitable base for the reaction of (IIa) with (IIIa), or an alkali metal hydride (e.g.
 20 sodium hydride), followed where necessary by removing any protecting groups present. The reaction preferably takes place in an inert solvent such as an ether (e.g. tetrahydrofuran) optionally mixed with a ketone (e.g. tertiary butyl methyl ketone), a ketone (e.g. acetone
 25 or methyl ethyl ketone), or a dipolar aprotic solvent (e.g. dimethylformamide). The reaction conveniently takes place at a temperature of from about 10°C to reflux.

When R^{5a} is an alkoxycarbonyl group such as methoxycarbonyl conversion to a carboxyl group may be effected by hydrolysis using a base such as an alkali metal hydroxide or carbonate (e.g. sodium hydroxide, lithium hydroxide, potassium hydroxide or potassium carbonate) in the presence of an organic solvent such as an ether (e.g. dioxan or tetrahydrofuran) conveniently mixed with water. The reaction may conveniently be effected at a temperature in the range of from about ambient to reflux. Alternatively, acid hydrolysis may be used, for example using an inorganic acid such as hydrochloric acid in an organic solvent such as an ether (e.g. dioxan or tetrahydrofuran) conveniently mixed with water. The reaction may conveniently be effected at a temperature in the range of about ambient to about 80°C. When R^{5a} is a t-butoxycarbonyl group the hydrolysis may conveniently be effected using trifluoroacetic acid at about ambient temperature.

According to another process (B), a compound of formula (I), in which R¹ is CN attached at the ring 2-position, may be prepared by reacting a compound of formula (IV)




with a compound of formula (V)



or a corresponding thiol. A compound of formula (V) is initially treated with a suitable base such as sodium hydride to form an alkali metal salt which is reacted with (IV), preferably in an inert solvent such as dimethyl sulphoxide and conveniently at a temperature within the range of about room temperature and about 100°C. The thiol derivative may conveniently be treated with a suitable base such as an alkali metal alkoxide (e.g. sodium methoxide or potassium t-butoxide) and reacted with (IV) in the presence of a suitable solvent (e.g. an alcohol such as methanol or an ether such as tetrahydrofuran) at a temperature of from about ambient to reflux.

Another process (C) for preparing a compound of formula (I) in which X is oxygen and R² is aryl lower alkoxy or heteroaryl lower alkoxy comprises treating a compound of formula (VI)



wherein R^{5a} is as defined previously, with an arylalkyl or heteroarylalkyl halide in the presence of a suitable base such as an alkali metal carbonate (e.g. potassium carbonate) or an alkali metal hydride (e.g. sodium hydride), followed where necessary by removing any protecting groups present. The displacement reaction

preferably takes place in an inert solvent such as a ketone (e.g. acetone or methyl ethyl ketone) or a dipolar aprotic solvent such as dimethylformamide, conveniently at a temperature from about room
5 temperature to reflux. Alternatively, a compound of formula (VI) may be treated with an arylalkyl or heteroarylalkyl alcohol in the presence of a triarylphosphine, such as triphenylphosphine, and a dialkyl ester, such as the diisopropyl or diethyl ester
10 of azodicarboxylic acid, followed where necessary by removing any protecting groups present. The reaction preferably takes place in an inert solvent such as tetrahydrofuran, preferably at a temperature from about 0°C to about room temperature.


15

Compounds of general formula (I) in which R⁵ is a carboxylic acid isostere may be prepared by the methodologies described herein, or conveniently from the corresponding acid. For example compounds of
20 formula (I) in which R⁵ is alkylsulphonylcarbamoyl, arylsulphonylcarbamoyl or heteroarylsulphonylcarbamoyl, X is oxygen and R² is aryl lower alkoxy or heteroaryl lower alkoxy are prepared by treating a compound of formula (I) wherein R⁵ is carboxy with an activating
25 agent such as N,N'-carbonyldiimidazole in an inert solvent such as dichloromethane followed by reaction with the sodium salt of an alkylsulphonamide, arylsulphonamide or heteroarylsulphonamide and removal of any protecting groups present. The reaction
30 preferably takes place in a dipolar aprotic solvent such as dimethylformamide at about room temperature.

"Prodrugs" of compounds of general formula (I), in which R⁵ is a carboxylic acid, such as carboxylic acid
35 alkyl esters including acyloxyalkyl esters, may conveniently be prepared from the corresponding acid,

for example by reaction with an appropriate alkyl halide, including acyloxyalkyl halides, in the presence of a suitable base such as an alkali metal carbonate (e.g. potassium carbonate) or an alkali metal hydride (e.g. sodium hydride). The reaction preferably takes place in a dipolar aprotic solvent such as dimethylformamide at about room temperature.

Intermediate compounds of formula (II), where R^2 represents aryl lower alkoxy or heteroaryl lower alkoxy and X represents an oxygen atom, may conveniently be prepared by treating a compound of formula (VII)



15

where R^{1a} is CHO, to introduce the groups R^2 and R^1 conveniently in that sequence.

The group R^2 may conveniently be introduced by reaction with an aryl or heteroaryl halide, or with an aryl or heteroarylmethanol according to the process (C) procedures.

When R^1 is CN this group may be introduced by conventional means, for example by treating the corresponding aldehyde with hydroxylamine or a salt thereof (e.g. the hydrochloride salt) to provide an oxime which may then be dehydrated, for example using acetic anhydride. Alternatively, the aldehyde may be reacted with a nitroalkane in acetic acid, preferably

in the presence of sodium acetate or ammonium hydrogen phosphate, according to the procedure described in JACS 1961, 83, 2203. Alternatively, the aldehyde may be reacted with hydroxylamine-O-sulphonic acid preferably
5 in an alcoholic solvent (e.g. aqueous ethanol) and conveniently at a temperature about room temperature, followed by treatment with an alkali metal hydroxide such as sodium hydroxide.

- 10 When R^1 is CH_2CN this group may be introduced by reducing the aldehyde to CH_2OH , followed by conventional conversion of the hydroxy group to a suitable leaving group such as halo, alkylsulphonyloxy or arylsulphonyloxy, which is then converted to CH_2CN
15 by a conventional displacement reaction using an inorganic nitrile.

When R^1 is $CH=CHCN$ or $CH=CHCO_2H$ these groups may be introduced by a conventional Wittig or Horner-Emmons
20 reaction on the corresponding aldehyde, followed by removal of any protecting groups where necessary.

It will be appreciated that the aforementioned conversions may also be applied to a compound in which
25 one or both of the formula (VII) hydroxyl groups is/are replaced by SH to provide a compound in which X is sulphur and/or R^2 is aryl lower alkylthio or heteroaryl lower alkylthio.

- 30 Compounds of formula (III) where Y is a bromine atom may conveniently be prepared by reaction of the corresponding compound in which Y is hydrogen with N-bromosuccinimide and azobisisobutyronitrile in an inert solvent such as chloroform at a temperature at about
35 reflux.

Compounds of formula (III) where Y is a bromine atom may also be prepared by reaction of the corresponding compound in which Y is hydroxyl with carbon tetrabromide and triphenylphosphine in an inert solvent
5 such as dichloromethane at a temperature at about ambient temperature.


Compounds of formula (III) where Y is a bromine or chlorine atom may also be prepared by reaction of the
10 corresponding compound in which Y is hydroxyl with thionyl bromide, or thionyl chloride in an inert solvent such as toluene at a temperature at about ambient temperature.

Compounds of formula (III) where Y is alkylsulphonyloxy such as methanesulphonyloxy or arylsulphonyloxy such as p-toluenesulphonyloxy may conveniently be prepared by reaction of the corresponding compound in which Y is hydroxyl with an alkyl- or aryl-sulphonyl halide such
20 as methane- or p-toluene-sulphonyl chloride in the presence of a base, such as pyridine. The reaction may be carried out in an inert solvent such as a halogenated hydrocarbon (e.g. dichloromethane) at a temperature from about ambient to reflux.

25 Compounds of formula (IIIa) where Y is a bromine atom and the cation $N^+H_2R^6R^7$ is derived from a classical chiral base (e.g. (-)-ephedrine), may be prepared by reaction of compounds of formula (III), where Y is a
30 bromine atom and R^{5a} represents carboxy, with a suitable chiral base (e.g. (-)-ephedrine), in the presence of a racemisation enhancing agent (e.g. tetra-n-butylammonium bromide). The reaction is carried out
35 in an inert solvent such as ethyl acetate at a temperature at about ambient temperature.

Compounds of formula (IV) in which R^2 is aryl lower alkoxy or heteroaryl lower alkoxy may conveniently be prepared from corresponding compounds in which R^2 is hydroxyl according to the procedure described in process (C) above. The phenol precursors are either known compounds described, for example, by S. M. Kelly, *Helv. Chim. Acta* 1984, volume 67, p1572-1579 or may be prepared by similar methods to those described therein. The corresponding thiols may also be used to prepare compounds of formula (IV) in which R^2 is aryl lower alkylthio or heteroaryl lower alkylthio.


Compounds of formula (VI), may conveniently be prepared from compounds of formula (VII), in which R^{1a} represents CHO, by first treating said compound of formula (VII), with an allyl halide (e.g. allyl bromide) in the presence of a suitable base such as a carbonate (e.g. potassium carbonate) to give a compound of formula (VIII)



The reaction is facilitated by the addition of potassium iodide and tetrabutylammonium bromide. The reaction preferably takes place in an inert solvent such as a ketone (e.g. acetone or methyl ethyl ketone) at a temperature from about room temperature to reflux. Alternatively the reaction may be carried out in the presence of an alkali metal hydride such as sodium hydride in a dipolar aprotic solvent such as

dimethylformamide at a temperature from about room temperature to about 100°C.

The group CHO in a compound of formula (VIII) may then
5 be converted to the desired R¹ group using the procedures described above. Said compound may then be converted to a compound of formula (IX)



10

by treatment with a compound of formula (III) according to the procedure in process (A) above. Finally, a compound of formula (IX) may be converted to a compound of formula (VI) by reaction with 1,4-

15

diazabicyclo[2.2.2]octane and tris(triphenylphosphine)rhodium(I) chloride, preferably in an alcoholic solvent (e.g. aqueous ethanol) and conveniently at a temperature from about room temperature to reflux.

20

Intermediates of formula (V), thiol derivatives thereof and those of formula (III) in which Y is hydrogen or hydroxyl are either known compounds described, for example, in J. Med. Chem., 17, 34 (1974), Org. Synth.

25

Coll. Vol. I, page 336, Ark. Kemi, 24B(15), 1947, EP-A-0617001 and Tetrahedron Letters, 36, 1759, (1995) or may be prepared by using methods analogous to those described therein.

Intermediates of formula (V) may also be prepared from the corresponding keto-esters by reduction with sodium borohydride in an inert solvent such as tetrahydrofuran at a temperature at or about 0°C, followed by
5 hydrolysis using a base such as an alkali metal hydroxide (e.g. sodium hydroxide) in the presence of an organic solvent such as an ether (e.g. dioxan) conveniently mixed with water. The reaction may be effected at a temperature from about ambient to reflux.

10 Compounds of formula (VII) are known compounds which are readily available from commercial sources. The corresponding mercaptans are either known in the art or may be prepared from compounds of formula (VII) using
15 routine procedures.

According to a further feature of the invention, acid addition salts of the compounds of this invention are prepared by reaction of the free base with the
20 appropriate acid, by the application or adaptation of known methods. For example, the acid addition salts of the compounds of this invention are prepared either by dissolving the free base in aqueous or aqueous-alcohol solution or other suitable solvents containing the
25 appropriate acid and isolating the salt by evaporating the solution, or by reacting the free base and acid in an organic solvent, in which case the salt separates directly or can be obtained by concentration of the solution.

30 The parent compounds of this invention can be regenerated from the acid addition salts by the application or adaptation of known methods. For example, parent compounds of the invention can be
35 regenerated from their acid addition salts by treatment with an alkali, such as aqueous sodium bicarbonate solution or aqueous ammonia solution.

Metal salts of compounds of the present invention may be obtained by contacting a hydride, hydroxide, carbonate or similar reactive compound of the chosen metal in an aqueous or organic solvent with the free acid form of the compound. The aqueous solvent employed may be water or it may be a mixture of water with an organic solvent, preferably an alcohol such as methanol or ethanol, a ketone such as acetone, an aliphatic ether such as tetrahydrofuran, or an ester such as ethyl acetate. Such reactions are normally conducted at ambient temperature but they may, if desired, be conducted with heating.

Amine salts of compounds of the present invention may be obtained by contacting an amine in an aqueous or organic solvent with the free acid form of the compound. Suitable aqueous solvents include water and mixtures of water with alcohols such as methanol or ethanol, ethers such as tetrahydrofuran, nitriles such as acetonitrile, or ketones such as acetone. Amino acid salts may be similarly prepared.

The parent compounds of this invention can be regenerated from the base addition salts by the application or adaptation of known methods. For example, parent compounds of the invention can be regenerated from their base addition salts by treatment with an acid, such as hydrochloric acid.

As will be self-evident to those skilled in the art, some of the compounds of this invention do not form stable acid addition salts. However, acid addition salts are most likely to be formed by compounds of this invention having a nitrogen-containing heteroaryl group.

As well as being useful in themselves as active compounds, salts of compounds of the invention are useful for the purposes of purification of the compounds, for example by exploitation of the
5 solubility differences between the salts and the parent compounds, side products and/or starting materials by techniques well known to those skilled in the art.

It will be appreciated that it may be necessary to
10 protect any labile groups such as hydroxyl groups when performing certain of the reactions described above. Conventional protection and subsequent deprotection procedures may be employed. Thus, for example, a hydroxyl group may conveniently be protected as an
15 acyloxy group (e.g. acetoxy); the hydroxyl group may be regenerated by base-catalysed hydrolysis. Other conventional hydroxyl protecting groups may also be employed, for example as described by in Protective Groups in Organic Synthesis by Theodora W. Greene (John
20 Wiley & Sons Inc. 1991).

The following Examples illustrate the preparation of the compounds according to the invention and the Reference Examples illustrate the preparation of the
25 intermediates. It is to be understood that the Examples are purely illustrative, and are not intended to limit the invention in any way.

In the nuclear magnetic resonance (NMR) spectra,
30 chemical shifts are expressed in ppm relative to tetramethylsilane. Abbreviations have the following meanings:

s = singlet, d = doublet, t = triplet, q = quartet, m =
35 multiplet, dd = doublet of doublets.

Chiral HPLC determination to establish the enantiomeric purity of individual isomers, as the free acids, was carried out using a Chiralpak AD column (Diacel) and a mobile phase of heptane/isopropanol/trifluoroacetic acid (400/100/1, by volume), with UV detection at 254nm.

EXAMPLE 1

10 (RS)-(2-Chlorophenyl)-[2-cyano-5-(4-pyridylmethoxy)phenoxy]acetic acid

A solution of Reference Example 7 (0.35g) in dioxan (25ml) was treated with 1N sodium hydroxide (5ml) and stirred at ambient temperature for 6 hours. Water (50ml) was added and the solution acidified to pH 2 with 2N hydrochloric acid. The mixture was extracted three times with ethyl acetate (25ml) and the combined extracts were washed with brine (25ml), dried over magnesium sulphate and evaporated. The residue was dissolved in 1N sodium hydroxide (10ml) and the solution acidified to pH 2 by addition of concentrated hydrochloric acid. The resulting solid was filtered and washed with water to give a pale yellow solid, which was recrystallised from isopropanol to provide the title compound (100mg), m.p. 225-226°C. [Elemental analysis:- C,63.98; H,3.80; N,7.07%. Calculated:- C,63.88; H,3.83; N,7.10%].

EXAMPLE 2

30 (RS)-[2-Cyano-5-(3-thienylmethoxy)phenoxy]-phenylacetic acid

A solution of Reference Example 8 (600mg) in dioxan (17ml) was treated with 1N sodium hydroxide (4.74ml) and stirred at room temperature for 1 hour. The solution was brought to pH 7 by addition of 2N hydrochloric acid and evaporated to remove dioxan. The residue was diluted with water and the solution adjusted to pH 1. The mixture was extracted with ethyl

acetate, washed with water, dried and evaporated. The residue was triturated with pentane to give the title compound as a yellow solid (440mg). [Elemental analysis:- C, 65.7; H, 4.40; N, 3.69%. Calculated:-

- 5 C, 65.7; H, 4.14; N, 3.83%]. ¹H NMR (CDCl₃): 5.0 (2H, s), 5.65 (1H, s), 6.5 (1H, s), 6.6 (1H, d), 7.05 (1H, d), 7.2-7.4 (5H, m), 7.45 (1H, d), 7.6 (2H, d).

EXAMPLE 3

- 10 (RS)-(2-Chlorophenyl)-[2-cyano-5-(3-thienylmethoxy)phenoxy]acetic acid

- A solution of Reference Example 11 (1.5g) in dioxan (20ml) was treated with 1N sodium hydroxide (13ml) and stirred at ambient temperature for 1 hour. Water (30ml)
15 was added and the solution acidified to pH 1 by addition of 2N hydrochloric acid. The mixture was extracted four times with ethyl acetate (100ml). The combined extracts were washed four times with water (50ml), four times with brine (50ml), dried over
20 magnesium sulphate and evaporated. Pentane (50ml) was added to the residual oil followed by evaporation giving a cream coloured solid which was dissolved in ether (20ml) and reprecipitated by addition of pentane (20ml) to give the title compound (1.5g) as a cream
25 coloured solid, m.p. 68-70°C. [Elemental analysis:- C, 60.29; H, 4.47; N, 3.26%. Calculated for C₂₀H₁₄ClNO₄S·0.5Et₂O:- C, 60.07; H, 3.52; N, 3.50%].

EXAMPLE 4

- 30 (RS)-[5-(1,3-Benzodioxol-5-ylmethoxy)-2-cyanophenoxy]phenylacetic acid

- A solution of Reference Example 16 (0.75g) in dioxan (10ml) was treated with 1N sodium hydroxide (5.4ml) and stirred at ambient temperature for 1.5 hours. Water
35 (10ml) was added and the solution acidified to pH 2 by

addition of 2N hydrochloric acid. The mixture was extracted three times with ethyl acetate (25ml). The combined extracts were washed with brine (25ml), dried over magnesium sulphate and evaporated. The residual yellow oil was purified by flash chromatography on silica eluting with a mixture of ethyl acetate and light petroleum (bp 40-60°C) (1:1, v/v). Fractions containing the required product were combined and evaporated. This material was further purified by flash chromatography on silica eluting initially with a mixture of light petroleum (bp 40-60°C) and ethyl acetate (5:1, v/v) then with a mixture of light petroleum (bp 40-60°C) and ethyl acetate (10:3, v/v). Fractions homogenous in the required product were combined and evaporated to give the title compound (1.5g) as a cream coloured solid, m.p. 68-70°C. [Elemental analysis:- C,66.36; H,4.95; N,2.85%. Calculated for $C_{23}H_{17}NO_6 \cdot 0.6H_2O$:- C,66.63; H,4.44; N,3.38%].

EXAMPLE 5

(RS)-[5-(1,3-Benzodioxol-5-ylmethoxy)-2-cyanophenoxy]-(2-trifluoromethylphenyl)acetic acid

A solution of Reference Example 19 (0.35g) in dioxan (5ml) was treated with 1N sodium hydroxide (2.16ml) and stirred at ambient temperature for 2 hours. Water (10ml) was added and the solution acidified to pH 1 with 2N hydrochloric acid. The mixture was extracted three times with ethyl acetate (20ml) and the combined extracts were washed with brine (20ml), dried over magnesium sulphate and evaporated. The residual yellow oil was purified by flash chromatography on silica eluting with a mixture of dichloromethane and methanol (95:5, v/v). Fractions homogenous in the required product were combined and evaporated. The residue was triturated with a mixture of diisopropyl ether and pentane to give the title compound (0.25g) as a white

solid, m.p. 137-138°C. [Elemental analysis:- C,61.08; H,3.48; N,3.11%. Calculated:- C,61.15, H,3.42; N,2.97%].

5 EXAMPLE 6

(RS)-[2-Cyano-5-(3-thienylmethoxy)phenoxy]-(2-methylphenyl)acetic acid

A solution of Reference Example 22 (0.55g) in dioxan (10ml) was treated with 1N sodium hydroxide (4.5ml) and stirred at ambient temperature for 2 hours. Water (10ml) was added and the solution acidified to pH 1 with 2N hydrochloric acid. The mixture was extracted four times with ethyl acetate (100ml). The combined extracts were washed twice with water (10ml), twice with brine (10ml), dried over magnesium sulphate and evaporated. The residual pink solid was triturated with pentane (20ml). The solid was dissolved in ethyl acetate and the solution filtered through a pad of silica. Evaporation of the filtrate and trituration of the resulting solid with ether (10ml) gave the title compound (0.28g) as a colourless solid, m.p. 146-148°C. [Elemental analysis:- C,66.80; H,4.49; N,3.69; S,8.45%. Calculated:- C,66.50; H,4.52; N,3.69; S,8.47%].

25 EXAMPLE 7

(RS)-[5-(1,3-Benzodioxol-5-ylmethoxy)-2-cyanophenoxy]-(2-chlorophenyl)acetic acid

A solution of Reference Example 23 (0.35g) in dioxan (5ml) was treated with 1N sodium hydroxide (2ml) and stirred at ambient temperature for 1 hour. Water (10ml) was added and the solution acidified to pH 1 with 2N hydrochloric acid. The mixture was extracted three times with ethyl acetate (20ml). The combined extracts were washed with brine (20ml), dried over magnesium sulphate and evaporated. The residual yellow oil was purified by flash chromatography on silica eluting with a mixture of ethyl acetate and methanol (4:1, v/v).

Fractions homogenous in the required product were combined and evaporated. The residue was triturated with a mixture of diisopropyl ether and pentane to give the title compound (0.25g) as a white solid, m.p. 144-145°C. [Elemental analysis:- C,61.08; H,3.48; N,3.11%. Calculated:- C,61.15; H,3.42; N,2.97%].

EXAMPLE 8

(RS)-(2-Bromophenyl)-[2-cyano-5-(3-thienylmethoxy)phenoxy]acetic acid

A solution of Reference Example 28 (0.48g) in dioxan (5ml) was treated with 1N sodium hydroxide (3.14ml) and stirred at ambient temperature for 1.5 hours. Water (30ml) was added and the solution acidified to pH 2 with 2N hydrochloric acid. The mixture was extracted three times with ethyl acetate (50ml). The combined extracts were washed with water, dried over magnesium sulphate and evaporated. The residual light brown semi-solid was triturated with pentane to give the title compound (0.39g) as a white solid, m.p. 89-98°C.

EXAMPLE 9

(RS)-(3-Chlorophenyl)-[2-cyano-5-(3-thienylmethoxy)phenoxy]acetic acid

A solution of Reference Example 31 (1g) in dioxan (20ml) was treated with 1N sodium hydroxide (9ml) and stirred at ambient temperature for 1 hour. Water (10ml) was added, the mixture filtered and the filtrate acidified to pH 1 with 2N hydrochloric acid. The mixture was extracted four times with ethyl acetate (50ml). The combined extracts were washed with brine (50ml), dried over magnesium sulphate and evaporated. Ether (10ml) was added to the residual oil and the resulting cream coloured solid was purified by flash chromatography on silica eluting with ethyl acetate. Fractions homogenous in the required product were

combined and evaporated. The residue was dissolved in ether (10ml) and pentane (10ml) was added to give the title compound (0.3g) as a colourless solid, m.p. 134-136°C. [Elemental analysis:- C, 60.72; H, 4.62; N, 2.98; S, 7.08; Cl, 7.91%. Calculated:- C, 60.48; H, 4.38; N, 3.20; S, 7.33; Cl, 8.11%].

EXAMPLE 10

(R)-(2-Chlorophenyl)-[2-cyano-5-(3-thienylmethoxy)phenoxy]acetic acid and
(S)-(2-chlorophenyl)-[2-cyano-5-(3-thienylmethoxy)phenoxy]acetic acid

The product of Example 3 was separated into its (R) and (S) enantiomers by chiral HPLC using the following conditions:- Chiracel OD column; mobile phase of isopropanol/trifluoroacetic acid/heptane (10 : 0.25 : 90, v/v); flow rate 1ml/minute; temperature ambient; UV detection at 270nm.

EXAMPLE 11

(RS)-[2-Cyano-5-(4-pyridylmethoxy)phenoxy]-phenylacetic acid

A stirred solution of (RS)-mandelic acid (0.304g) in dry dimethyl sulphoxide (10ml) was treated with sodium hydride (0.16g, 60% dispersion in mineral oil) at room temperature. After 15 minutes Reference Example 32 (0.457g) was added and stirring was continued for 1.25 hours at ambient temperature, then at 50°C for 30 minutes. Water (20ml) was added and the solution acidified to pH 2.5 with 2N hydrochloric acid. A small amount of sodium chloride was added and the mixture extracted three times with ethyl acetate (50ml). The combined extracts were washed with brine, dried over magnesium sulphate and evaporated. The residue was triturated with pentane, the solid washed with ether and recrystallised from ethanol to give the title

compound (0.08g) as a pale yellow solid, m.p. 218-220°C. [Elemental analysis:- C,69.77; H,4.43; N,7.74%. Calculated:- C,69.99; H,4.48; N,7.78%].

EXAMPLE 12

5 (RS)-[2-Cyano-5-(3-thienylmethoxy)phenoxy]-(2-fluorophenyl)acetic acid

A solution of Reference Example 33 (0.66g) in dioxan (6ml) was treated with 1N sodium hydroxide (4.98ml) and stirred at ambient temperature for 1.5 hours. Water
10 (50ml) was added and the solution acidified to pH 2 with 2N hydrochloric acid. The mixture was extracted three times with ethyl acetate (30ml). The combined extracts were washed twice with water (10ml), dried over magnesium sulphate and evaporated. The residual
15 green coloured oil (0.9g) was triturated twice with pentane (30ml) affording the title compound as a pale yellow solid, m.p. 159-161°C. [Elemental analysis:- C,62.4; H,3.89; N,3.49; S,7.95%. Calculated:- C,62.65; H,3.68; N,3.65; S,8.36%].

20

EXAMPLE 13

(RS)-[2-Cyano-5-(4-pyridylmethoxy)phenoxy]-(2-methylphenyl)acetic acid

A stirred mixture of (RS)- α -hydroxy-(2-methylphenyl)acetic acid [7.0g; I.I. Lipkin and A.V. Ljubimowa Zh. Obshch. Khim 1948, 18, 701 (C.A. 1949, 43, 188)] and Reference Example 32 (9.5g) in dry
25 dimethyl sulphoxide was treated portionwise with sodium hydride (4.0g of 60% w/w dispersion in mineral oil, 100mmol) over 1 hour. The reaction was stirred a
30 further 3 hours at ambient temperature before being concentrated under reduced pressure. The residue was partitioned between water (500ml) and three amounts of dichloromethane (200ml). The aqueous layer was
35 acidified to pH 2-3 with concentrated hydrochloric acid

and extracted with ethyl acetate (1000ml). The organic layer was dried over magnesium sulphate and heated on a steam bath until the total volume was reduced to 100ml. On standing a white solid was deposited.

- 5 Recrystallisation from isopropanol gave the title compound (10.0g) as a white solid, m.p. 198-201°C. [Elemental analysis:- C,70.42; H,4.79; N,7.56%. Calculated:- C,70.58; H,4.85; N,7.48%].

10 EXAMPLE 14

(RS)-[2-Cyano-5-(3-thienylmethoxy)phenoxy]-(2-trifluoromethylphenyl)acetic acid

- A solution of Reference Example 34 (0.8g) in dioxan (40ml) was treated with 1N sodium hydroxide (5ml) and stirred at ambient temperature for 1 hour. Water (40ml) was added and the solution acidified to pH 1 with 2N hydrochloric acid. The mixture was extracted four times with ethyl acetate (80ml). The combined extracts were washed with water (10ml) then brine (10ml), dried over magnesium sulphate and evaporated. The residual gum was triturated with a mixture of diethyl ether (20ml) and pentane (5ml) and the resulting solid (0.38g) was dissolved in ethyl acetate. This solution was filtered through a pad of silica. Evaporation of the filtrate afforded the title compound (0.18g) as a colourless solid, m.p. 38-40°C. [Elemental analysis:- C,58.55; H,3.66; N,2.98%. Calculated:- C,58.19; H,3.25; N,3.23%].

30 EXAMPLE 15

(RS)-(2-Bromophenyl)-[2-cyano-5-(4-pyridylmethoxy)phenoxy]acetic acid

- A stirred solution of (RS)- α -hydroxy-(2-bromophenyl)acetic acid (0.46g) in dry dimethyl sulphoxide (15ml) was treated with sodium hydride (0.16g, 60% dispersion in mineral oil) at room

temperature. After 1 hour Reference Example 32 (0.46g) was added and stirring was continued for 24 hours at ambient temperature. Water (50ml) was added and the pH of the solution adjusted to 3-4 with 2N hydrochloric acid and the mixture extracted twice with ethyl acetate (75ml). The combined extracts were dried over magnesium sulphate, evaporated and the residue purified by flash chromatography on silica eluting initially with ethyl acetate then with a mixture of ethyl acetate and methanol (4:1, v/v). Fractions homogenous in the required product were combined and evaporated. The residual yellow oil was dissolved in 1N sodium hydroxide (10ml), the solution filtered and the filtrate acidified to pH 3. The resulting yellow solid (0.22g) was washed well with water and recrystallised from isopropanol affording the title compound (0.1g) as a pale yellow solid, m.p. 171-172°C. [Elemental analysis:- C,57.1; H,4.14; N,6.09%. Calculated:- C,57.42; H,3.44; N,6.38%].

20

EXAMPLE 16

(RS)-[2-Cyano-5-(4-pyridylmethoxy)phenoxy]-(2-trifluoromethylphenyl)acetic acid, monohydrochloride

A stirred solution of (RS)- α -hydroxy-(2-trifluoromethylphenyl)acetic acid (1.1g; R. Belcher et al., Analytica Chimica Acta, 1954, 10, 34) in dry dimethyl sulphoxide (40ml), at room temperature, was treated portionwise with sodium hydride (0.4g, 60% dispersion in mineral oil). After stirring for 0.75 hours at ambient temperature Reference Example 32 (1.14g) was added and stirring was continued for 8 hours. The reaction mixture was stood at room temperature for 3 days then evaporated. The residue was partitioned between water and dichloromethane. The aqueous phase was acidified to pH 3 with concentrated hydrochloric acid and extracted three times with ethyl

acetate. The combined extracts were dried over magnesium sulphate, evaporated and the residue triturated with diethyl ether to give a yellow solid. Recrystallisation from isopropanol afforded the title

5 compound (0.1g) as a white solid, m.p. 200°C (dec)

[Elemental analysis:- C, 57.22; H, 3.24; N, 6.10%.

Calculated for $C_{22}H_{15}F_3N_2O_4 \cdot HCl$:- C, 56.84; H, 3.46; N, 6.03%].

10 EXAMPLE 17

(S)-[2-Cyano-5-(4-pyridylmethoxy)phenoxy]-(2-methylphenyl)acetic acid

A mixture of Example 13 (6.0g) and (-)-ephedrine (3.0g) was dissolved in ethanol (50ml) and allowed to stand at ambient temperature for 18 hours. The resultant solid was collected and recrystallised from ethanol to leave a white solid (3.3g). A sample of this solid (0.5g) was stirred in water (50ml) and treated with 1N hydrochloric acid until the pH was 2-3. After stirring a further 15 minutes, the mixture was extracted twice with dichloromethane (50ml). The combined extracts were dried over magnesium sulphate and evaporated. The residue was recrystallised from ethyl acetate to leave the title compound (0.2g) as a white fluffy solid, m.p.

25 215°C (dec); $[\alpha]_D^{20} +125^\circ$ (c=0.005, dimethyl sulphoxide). [Elemental analysis:- C, 70.34; H, 4.89; N, 7.53%. Calculated:- C, 70.58; H, 4.85; N, 7.48%].

EXAMPLE 18

30 (RS)-(2-Chlorophenyl)-[2-cyano-5-(pyridazin-4-ylmethoxy)phenoxy]acetic acid

A solution of Reference Example 35 (0.2g) in dioxan (6ml) was treated with 1N sodium hydroxide (1.47ml) and stirred at ambient temperature for 1 hour. The reaction mixture was evaporated at 40°C, the residue diluted

with water (6ml) and the solution acidified to pH 3 with 2N hydrochloric acid. The resulting solid was filtered, stirred with water (5ml) for 1 hour, washed with ether (6ml) and dried under vacuum at 40°C

- 5 affording the title compound (0.048g) as an off-white amorphous solid, m.p. 203-205°C. [Elemental analysis:- C,60.9; H,3.71; N,10.3%. Calculated:- C,60.7; H,3.57; N,10.6%].

10 EXAMPLE 19

(RS)-[5-(1,3-Benzodioxol-5-ylmethoxy)-2-cyanophenoxy]-
(2-methylphenyl)acetic acid

- A stirred solution of (RS)- α -hydroxy-(2-methylphenyl)acetic acid (11g) and Reference Example 36 (14.4g) in dry dimethyl sulphoxide (100ml), at room temperature, was treated portionwise with sodium hydride (5.94g, 60% dispersion in mineral oil) over 1 hour. After stirring for 18 hours at ambient temperature the reaction mixture was evaporated and the residue dissolved in water (500ml). The solution was washed three times with ethyl acetate (100ml), and the aqueous phase was acidified to pH 1.5 and extracted three times with ethyl acetate (300ml). The combined extracts were dried over magnesium sulphate, evaporated and the residual brown gum purified by flash chromatography on silica eluting with a mixture of ethyl acetate and pentane (3:2, v/v). Three of the fractions containing the required product were combined and evaporated. The residual pale yellow solid was trituated with a mixture of diisopropyl ether and pentane affording the title compound (6.85g) as a cream coloured solid, m.p. 125-126°C. [Elemental analysis:- C,69.06; H,4.59; N,3.36%. Calculated:- C,68.65; H,4.66; N,3.28%]. Two latter fractions containing the required product were combined and evaporated. The residual pale
- 35

yellow solid was triturated with a mixture of diisopropyl ether and pentane affording a further 3.8g of the title compound as a cream coloured solid, m.p.

124-125°C. [Elemental analysis:- C,68.47; H,4.80;

5 N,3.27%. Calculated for $C_{24}H_{19}NO_6 \cdot 0.1H_2O$:- C,68.71; H,4.62; N,3.34%].

EXAMPLE 20

(RS)-(2-Chlorophenyl)-[2-cyano-5-(isothiazol-4-ylmethoxy)phenoxy]acetic acid

A solution of Reference Example 37 (0.43g) in dioxan (30ml) was treated with 1N sodium hydroxide (3ml) and stirred at ambient temperature for 2 hours. The reaction mixture was evaporated, water (10ml) was added
15 to the residue and the solution washed with ether (15ml), then acidified to pH 1 with 2N hydrochloric acid. The mixture was extracted twice with ethyl acetate (40ml). The combined extracts were washed twice with water (15ml), then with brine (15ml), dried over
20 magnesium sulphate and evaporated. The residual gum was triturated with a mixture of pentane and ether (20ml, 2:1, v/v) affording the title compound (0.34g) as a white solid, m.p. 194-197°C.

25 EXAMPLE 21

(RS)-[2-Cyano-5-(3-pyridylmethoxy)phenoxy]-phenylacetic acid

A solution of Reference Example 38 (0.2g) in dioxan (10ml) was treated with 1N sodium hydroxide (1.2ml) and
30 stirred at ambient temperature for 2 hours. The reaction mixture was acidified to pH 5 with 2N hydrochloric acid and extracted with ethyl acetate. The organic extracts were washed with brine, dried over magnesium sulphate, evaporated and the residue purified
35 by flash chromatography on silica eluting with a

mixture of pentane and ethyl acetate (3:1, v/v). Fractions homogenous in the required product were combined and evaporated affording the title compound (0.39g) as a yellow solid, m.p. 201-202°C.

5

EXAMPLE 22

(RS)-[2-Formyl-5-(3-thienylmethoxy)phenoxy]-phenylacetic acid

10 A solution of Reference Example 42 (0.50g) in dioxan (10ml) was treated with 1N sodium hydroxide (3.63ml) and stirred at 25°C for 2 hours. The solution was treated with water (40ml), acidified to pH 2 with 3N hydrochloric acid and extracted three times with ethyl acetate (75ml). The combined extracts were washed with
15 brine (70ml), dried and evaporated. The residue was triturated with ether to give the title compound (0.17g) as a cream solid, m.p. 172-174°C. [Elemental analysis:- C,64.2; H,4.34%. Calculated for $C_{20}H_{16}O_5S \cdot 0.33H_2O$:- C,64.2; H,4.49%].

20

EXAMPLE 23

(RS)-N-([2-Cyano-5-(3-thienylmethoxy)phenoxy]phenylacetyl)-4-isopropylbenzenesulphonamide.

25 A solution of Example 2 (0.73g) in dry dichloromethane (50ml) was treated with N,N' carbonyldiimidazole (0.36g) and stirred at 25°C for 2 hours, when evolution of carbon dioxide was complete. A solution of 4-isopropylbenzenesulphonamide (0.60g) in dry
30 dimethylformamide (20ml) was treated with sodium hydride (0.13g, 60% dispersion in mineral oil) and stirred at 25°C for 2 hours. This solution was then treated dropwise with the solution of acylimidazole prepared above and stirring was continued at 25°C for 8
35 hours. The reaction mixture was evaporated, the residue diluted with water (50ml) and extracted twice with

ethyl acetate. The extracts were washed with water, dried and evaporated to give an orange oil which was purified by flash chromatography on silica eluting with ether. Fractions homogenous in the required product
5 were combined and evaporated. The residual pale yellow solid (0.35g) was recrystallised from a mixture of ethyl acetate and pentane affording the title compound (0.20g) as colourless crystals, m.p. 187-189°C. [Elemental analysis:- C, 63.7; H, 4.79; N, 5.12%.
10 Calculated:- C, 63.7; H, 5.17; N, 5.17%].

EXAMPLE 24

(RS)-[2-Cyano-5-(4-pyridylmethoxy)phenoxy]-(2-methylphenyl)acetic acid, acetoxy methyl ester

15 A mixture of Example 13 (0.6g) in dimethylformamide (50ml) was treated at room temperature under argon with sodium hydride (0.072g, 60% dispersion in oil) and stirred for 30 minutes. Bromomethyl acetate (0.24ml) was added and the mixture stirred 2 hours. The reaction
20 mixture was evaporated and the residue purified by flash chromatography on silica eluting with a mixture of dichloromethane and methanol (99:1, v/v). Fractions homogenous in the required product were combined and evaporated. The residue was triturated with pentane
25 affording the title compound (0.34g) as a white solid, m.p. 127-130°C [Elemental analysis:- C, 67.13; H, 4.83; N, 6.24%; Calculated:- C, 67.26; H, 4.97; N, 6.27%].

EXAMPLE 25

30 Sodium (S)-[2-cyano-5-(4-pyridylmethoxy)phenoxy]-(2-methylphenyl)acetate

A suspension of Example 17 (19.5g) in water (195ml) was treated with 0.1N sodium hydroxide (510ml) and stirred at 25°C for 15 minutes. The mixture was filtered from a
35 trace of insoluble solid and the filtrate was freeze dried. The residue was triturated with ether, dried at 50°C/0.1mm/2 hour and equilibrated 25°C/760mm/2 days,

giving the title compound (15.0g) as a colourless solid, m.p. 191-193°C(dec), softens at 130°C. [Elemental analysis:- C,63.8; H,4.49; N,6.59; H₂O,4.71%. Calculated for C₂₂H₁₇N₂O₄Na•H₂O:- C,63.8; H,4.62; N,6.76; H₂O,4.35%].

EXAMPLE 26

Sodium (S)-(5-(1,3-benzodioxol-5-ylmethoxy)-2-cyanophenoxy)-(2-methylphenyl)acetate

- 10 Method A: A suspension of Example 35(a) (13.5g) in water (50ml) was treated with 0.1N sodium hydroxide (320ml) and stirred at 25°C for 30 minutes. The mixture was filtered from a trace of insoluble solid, the filtrate was freeze dried and the solid recrystallised
- 15 from butanol affording the title compound (8.15g) as a white solid, m.p. 218-222°C. [Elemental analysis:- C,65.5; H,4.15; N,3.38%. Calculated:- C,65.6; H,4.20; N,3.19%].
- 20 Method B: A suspension of Reference Example 72(a) (8.0g) in ethyl acetate (80ml) was stirred for 10 minutes with sulphuric acid (1N; 21ml) at about 20°C. The two layers were separated; the ethyl acetate solution was washed twice with water (20ml), filtered
- 25 and the filtrate was diluted with methanol (24ml). Aqueous sodium hydroxide (9N; about 1.5ml) was added until the solution reached pH 8.5 - 9 by pH paper. The solution was concentrated by distillation of about 85ml of volatile solvent. Ethyl acetate (80ml)
- 30 was added and the mixture further concentrated until crystallisation commenced (about 55ml distilled). The mixture was stirred at about 20°C, then with ice-bath cooling until crystallisation was complete. The product was filtered, washed with tert-butyl methyl

ether and dried by suction and then at about 50°C/
300mbar to give the title compound (4.63g; ee > 98%).

Method C: A suspension of Reference Example 72(a)
5 (220.0g) in ethyl acetate (1100ml) was stirred for 30
minutes with sulphuric acid (2N; 282ml) at about 20°C.
After about 5 minutes all the solid had dissolved.
The two layers were filtered. The organic phase was
separated and the ethyl acetate solution was washed
10 with water (220ml) and then with aqueous sodium
chloride (220ml). The organic solution was stirred
with charcoal (11.0g) then filtered and concentrated
under reduced pressure. The residue was treated with
toluene (300ml) and concentrated under reduced
15 pressure to leave of (S)-[5-(1,3-benzodioxol-5-
ylmethoxy)-2-cyanophenoxy]-(2-methylphenyl)acetic
acid (157.0g) as a solid. The product was dissolved
in ethanol (785ml) with warming. Aqueous sodium
hydroxide (9N; about 42ml) was added until the
20 solution reached pH 8.5 - 9 by pH paper then butanol
(1570ml) and water (40ml) were added.

This solution was combined with a solution prepared
in a similar manner from (415.3g) of Reference
25 Example 72(a) and stirred with heating to about 80°C
and concentrated by reducing the pressure as
necessary to maintain distillation at about this
temperature until crystallisation had started. The
mixture was left to cool to about 20°C, then filtered
30 and washed with butanol (350ml) and then with tert-
butyl methyl ether (650ml). The product was dried by
suction and then at about 70°C / 300mbar to give the
title compound (395.5g; ee > 99%).

EXAMPLE 27(RS)-(2-Chlorophenyl)-[2-cyano-3-fluoro-5-(3-thienylmethoxy)phenoxy]acetic acid

A solution of Reference Example 43 (0.95g) in dioxan
5 (30ml) was treated with 1N sodium hydroxide (25ml) and
stirred at ambient temperature for 4 hours. The
reaction mixture was treated with a further quantity of
1N sodium hydroxide solution (5ml) and stirring
continued for 30 minutes by which time tlc
10 (dichloromethane:methanol, 19:1 v/v) indicated the
reaction was complete. Water (100ml) was added, the
solution was washed diethyl ether (50ml), then
acidified to pH 1 by addition of 1N hydrochloric acid.
The mixture was extracted three times with diethyl
15 ether (50ml). The combined organic extracts were washed
with brine (50ml), dried over magnesium sulphate, and
evaporated. The residual viscous yellow oil was
crystallised from a mixture of ethyl acetate and
cyclohexane affording the title compound (0.55g) as a
20 cream coloured solid, m.p. 152-153°C. [Elemental
analysis:- C, 57.78; H, 3.17; N, 3.35; S, 7.41%.
Calculated:- C, 57.49; H, 3.11; N, 3.35; S, 7.66%].

EXAMPLE 28(RS)-[5-(Benzoxazol-6-ylmethoxy)-2-cyanophenoxy]-(2-chlorophenyl)acetic acid

A solution of Reference Example 47 (0.9g) in dioxan
(10ml) was treated with 1N sodium hydroxide (5ml) and
stirred at ambient temperature for 1.25 hours. The pH
30 of the resulting dark orange solution was adjusted to 8
by addition of 2N hydrochloric acid and the reaction
mixture concentrated under reduced pressure at 35°C.
The residual gum was dissolved in water (10ml), the
solution acidified to pH 2.5 by addition of 2N
35 hydrochloric acid and extracted with ethyl acetate. The
combined extracts were washed with water, with brine,

dried over magnesium sulphate, and evaporated. The residual dark brown oil (1.4g) was triturated with pentane (40ml) then with diethyl ether (20ml) giving a buff coloured solid (0.75g) which was purified by flash chromatography on silica eluting with a mixture of dichloromethane and methanol (14:1, v/v). Fractions homogenous in the required product were combined and evaporated affording the title compound (0.08g) as a buff coloured solid, m.p. 172-178°C. [Elemental analysis:- C, 62.70; H, 3.63; N, 6.25%. Calculated for $C_{23}H_{15}ClN_2O_5 \cdot 0.32H_2O$:- C, 62.7; H, 3.58; N, 6.36%].

EXAMPLE 29

(RS)-[2-Cyano-5-(4-pyridylmethoxy)phenoxy]-[2-(3-methyl)thienyl]acetic acid

A mixture of Reference Example 49 (1.14g) and 1N sodium hydroxide (5.7ml) in dioxan (50ml) was stirred at room temperature overnight. Further sodium hydroxide (5ml) was added and stirring was continued for a further 3 hours at room temperature. The clear solution was evaporated to dryness and the residue was azeotroped repeatedly with toluene. The resulting white powder was dissolved in anhydrous dimethyl sulphoxide (20ml) under nitrogen and the solution was treated with sodium hydride (0.37g, 60% dispersion in mineral oil). The mixture was stirred at room temperature for 30 minutes when Reference Example 32 (1.25g) was added in one portion. After stirring for 1 hour at room temperature the reaction mixture was partitioned between ethyl acetate (100ml) and 5% aqueous sodium bicarbonate solution (100ml). The aqueous phase was acidified to pH 5 by addition of acetic acid and extracted with ethyl acetate (100ml). The ethyl acetate extract was washed with water (50ml), dried over magnesium sulphate and evaporated. The residue was recrystallised from ethyl acetate affording the title compound (0.26g) as a white

solid; m.p. 153-154°C. [Elemental Analysis:- C, 61.3; H, 4.25; N, 7.21; S, 8.09%. Calculated for $C_{20}H_{16}N_2O_4S \cdot 0.5H_2O$:- C, 61.7; H, 4.37; N, 7.20; S, 8.23%].

5 EXAMPLE 30

(RS)-[(2-Cyano-5-(thiazol-5-ylmethoxy)phenoxy)-(2-methylphenyl)acetic acid

(RS)- α -Hydroxy-(2-methylphenyl)acetic acid (0.44g) was added portion wise to a stirred suspension of sodium
10 hydride (0.32g, 60% suspension in mineral oil) in anhydrous dimethyl sulphoxide (10ml). Reference Example 50 (0.62g) was added in one portion and the mixture stirred at room temperature for 1 hour. The reaction mixture was partitioned between ethyl acetate (100ml)
15 and 5% aqueous sodium hydrogen carbonate solution (100ml). The aqueous layer was washed with ethyl acetate (20ml), acidified to pH 5 by the addition of acetic acid and extracted with ethyl acetate. The extract was washed with water (10ml), dried over
20 magnesium sulphate, and evaporated. The residue was recrystallised from a mixture of ethyl acetate and cyclohexane affording the title compound (0.25g), m.p. 226-227°C. [Elemental analysis:- C, 60.5; H, 4.28; N, 6.85; S, 7.35%. Calculated for $C_{20}H_{16}N_2O_4S \cdot H_2O$:-
25 C, 60.3; H, 4.52; N, 7.04; S, 8.04%].

EXAMPLE 31

(RS)-(2-Chlorophenyl)-[2-cyano-3-fluoro-5-(4-pyridylmethoxy)phenoxy]acetic acid

30 A solution of Reference Example 51 (0.72g) in dioxan (20ml) and 1N sodium hydroxide (2ml) was stirred at room temperature for 30 minutes. The solution was diluted with water (50ml) and washed with diethyl ether (40ml). The aqueous layer was acidified to pH 4 by

addition of 1N hydrochloric acid and extracted three times with diethyl ether (40ml). The combined organic extracts were washed with saturated brine (50ml), dried over magnesium sulphate and evaporated. The residual
5 yellow gum was triturated with a mixture of diethyl ether and ethyl acetate (1:1, v/v) affording the title compound (0.7g) as a cream solid, m.p. 135-139°C.

[Elemental analysis:- C, 60.93; H, 3.70; N, 6.64%.
Calculated:- C, 61.09; H, 3.39; N, 6.79%].

10

EXAMPLE 32

(RS)-2-[(2-Chlorophenyl)-(1H-tetrazol-5-yl)methoxy]-4-(4-pyridylmethoxy)benzonitrile

A solution of Reference Example 58 (0.6g) in dry
15 dimethyl sulphoxide (20ml) under nitrogen was treated with sodium hydride (0.23g, 60% dispersion in mineral oil). After stirring at ambient temperature for 5 minutes Reference Example 32 (0.65g) was added and stirring continued for 45 minutes. Water (100ml) was
20 added, the mixture was acidified to pH 4 by addition of 1N hydrochloric acid and extracted three times with a mixture of ethyl acetate and methanol (60ml, 9:1 v/v). The separating funnel had to be washed with methanol at this stage to dissolve some insoluble material. The
25 combined extracts and methanol washings were concentrated and the residue diluted with water (100ml) and the pH of this solution adjusted to 4 by addition of 1N hydrochloric acid. The resulting solid was filtered and dried affording the title compound
30 (0.91g), as an off white solid m.p. 108-110°C.
[Elemental analysis:- C, 55.58; H, 3.81; N, 18.6%.
Calculated for $C_{21}H_{15}ClN_6O_2 \cdot 1.5H_2O$:- C, 56.0; H, 4.10; N, 18.66%].

35

EXAMPLE 33

(RS)-[3-Chloro-2-cyano-5-(4-pyridylmethoxy)phenoxy]-(2-chlorophenyl)acetic acid

A solution of Reference Example 60 (0.3g) in dioxan
5 (20ml) was treated with 1N sodium hydroxide (5ml) and
stirred at room temperature for 1 hour. After standing
at room temperature for 48 hours the solution was
diluted with water (30ml) and washed with diethyl ether
(30ml). The aqueous layer was acidified to pH 4 by
10 addition of 1N hydrochloric acid and extracted three
times with a mixture of methanol and ethyl acetate
(40ml, 1:9, v/v). The combined organic extracts were
washed with saturated brine (40ml), dried over
magnesium sulphate and evaporated affording the title
15 compound (0.15g) as a cream solid, m.p. 165-167°C.

[Elemental analysis:- C, 57.85; H, 3.59; N, 6.29%.
Calculated for $C_{21}H_{14}Cl_2N_2O_4 \cdot 0.5CH_3OH$:- C, 57.97;
H, 3.39; N, 6.79%].

20 EXAMPLE 34

(RS)-[5-(Benzoxazol-6-ylmethoxy)-2-cyanophenoxy]-(2-methylphenyl)acetic acid

A solution of Reference Example 69 (0.9g) in dioxan
(10ml) was treated with 1N sodium hydroxide (5ml) and
25 stirred at ambient temperature for 1.25 hours. The pH
of the resulting dark orange solution was adjusted to 8
by addition of 2N hydrochloric acid and the reaction
mixture concentrated under reduced pressure at 35°C.
The residual gum was dissolved in water (10ml), the
30 solution acidified to pH 2.5 by addition of 2N
hydrochloric acid and extracted with ethyl acetate. The
combined extracts were washed with water, with brine,
dried over magnesium sulphate, and evaporated. The
residual dark brown oil (1.4g) was triturated with
35 pentane (40ml) then with diethyl ether (20ml) giving a
buff coloured solid (0.75g) which was purified by flash

chromatography on silica eluting with a mixture of dichloromethane and methanol (14:1, v/v). Fractions homogenous in the required product were combined and evaporated affording the title compound as a buff
5 coloured solid, m.p. 172-178°C. [Elemental analysis:- C, 62.70; H, 3.63; N, 6.25%. Calculated for $C_{23}H_{15}ClN_2O_5 \cdot 0.32H_2O$:- C, 62.7; H, 3.58; N, 6.36%].

EXAMPLE 35

10 (a) (S)-[5-(1,3-Benzodioxol-5-ylmethoxy)-2-cyanophenoxy]-(2-methylphenyl)acetic acid

A stirred suspension of Reference Example 72(a) (0.58g) in ethyl acetate (50ml) was treated with 2N hydrochloric acid (20ml). After stirring at ambient
15 temperature for 40 minutes the organic layer was separated, washed with 2N hydrochloric acid (20ml) then with brine (20ml), dried over magnesium sulphate and evaporated. The residue was triturated with a mixture of ether and pentane affording the title compound
20 (0.24g) as a glassy white solid, m.p. 52-56°C. $[\alpha]_D^{20} +118^\circ$ (c=0.005, methanol). [Elemental analysis:- C, 69.09; H, 4.71; N, 3.33%. Calculated:- C, 69.06; H, 4.59; N, 3.36%].

25 (b) by proceeding in a similar manner to Example 35(a) but using Reference Example 72(b), may be prepared (S)-[5-(1,3-benzodioxol-5-ylmethoxy)-2-cyano-3-fluorophenoxy]-(2-methylphenyl)acetic acid.

30 EXAMPLE 36

(RS)-[5-(1,3-Benzodioxol-5-ylmethoxy)-2-cyanophenoxy]-(2-methylphenyl)acetic acid

A suspension of Reference Example 73 (123g) in dioxan (1000ml) was treated with 1N sodium hydroxide (600ml).
35 After stirring at room temperature for 2 hours the

reaction mixture was evaporated, the residue diluted with water (750ml) and the mixture washed with ethyl acetate (200ml). The aqueous phase was acidified to pH 1 by addition of concentrated hydrochloric acid and extracted twice with ethyl acetate (250ml). The combined extracts were evaporated and the residue triturated with a mixture of ethyl acetate and cyclohexane affording the title compound (99.6g) as a beige solid, m.p. 124-126°C.

EXAMPLE 37

(RS)-2-Cyano-[5-(4-(3-fluoropyridyl)methoxy)phenoxy]-(2-methylphenyl)acetic acid

A solution of Reference Example 74 (0.15g) in dioxan (10ml) was treated with 1N sodium hydroxide (0.5ml) and stirred at ambient temperature for 3.5 hours. A further quantity of 1N sodium hydroxide (0.5ml) was added and stirring continued for 1 hour. The reaction mixture was diluted with water (50ml), the pH adjusted to 3 by addition of 2N hydrochloric acid and mixture extracted three times with ethyl acetate (25ml). The combined extracts were washed with brine (25ml), dried over magnesium sulphate, and evaporated. The residue was triturated with diisopropyl ether and the resulting pale yellow solid washed with pentane.

Recrystallisation from a mixture of ethyl acetate and pentane afforded the title compound (0.75g) as white crystalline solid, m.p. 178-179°C. [Elemental

analysis:- C, 67.31; H, 4.44; N, 7.12%. Calculated:- C, 66.34; H, 4.37; N, 7.14%].

EXAMPLE 38

(RS)-2-[(2-Methylphenyl)-(1H-tetrazol-5-yl)methoxy]-4-(4-pyridylmethoxy)benzonitrile

A stirred solution of Reference Example 76 (0.42g) in dry dimethyl sulphoxide (10ml) under a nitrogen

atmosphere at room temperature was treated with sodium hydride (0.19g, 60% dispersion in mineral oil). After stirring at ambient temperature for 30 minutes Reference Example 32 (0.5g) was added and stirring continued 5 hours. Water (50ml) was added, the mixture washed with diethyl ether (50ml) and the pH of the aqueous phase adjusted to 4 with 1N hydrochloric acid. The resulting solid was washed twice with water (10ml) affording the title compound (0.34g) as a cream solid, m.p. 132-133°C. [NMR((CD₃)₂SO):- 2.3 (s,3H), 5.2 (s,2H), 6.8 (dd,1H), 7.0 (d,1H), 7.25 (m,4H), 7.4 (dd,2H), 7.5 (dd,1H), 7.7 (d,1H), 8.6 (dd,2H)].

EXAMPLE 39

15 (RS)-4-(1,3-Benzodioxol-5-ylmethoxy)-2-[(2-methylphenyl)-(1H-tetrazol-5-yl)methoxy]benzonitrile

A stirred solution of Reference Example 76 (0.34g) in dry dimethyl sulphoxide (10ml) under nitrogen at room temperature was treated with sodium hydride (0.16g, 60% dispersion in mineral oil). After stirring at room temperature for 30 minutes a solution of Reference Example 36 (0.5g) in dry dimethyl sulphoxide (5ml) was added and stirring continued for 18 hours. Water (50ml) was added, the mixture was washed with diethyl ether (50ml) and the pH of the aqueous phase adjusted to 2 by addition of 1N hydrochloric acid. The mixture was extracted four times with diethyl ether (50ml) and once with ethyl acetate (10ml). The combined organic extracts were washed three times with water (50ml), dried over magnesium sulphate and evaporated. Recrystallisation from a mixture of cyclohexane and ethyl acetate gave the title compound (0.49g) as a white solid, m.p. 106-109°C. [Elemental analysis:- C,66.04; H,4.64; N,15.47%. Calculated:- C,65.30; H,4.34; N,15.86%].

EXAMPLE 40

(RS)-[2-Cyano-3-fluoro-5-(4-pyridylmethoxy)phenoxy]-(2-methylphenyl)acetic acid

- 5 A solution of Reference Example 78 (0.64g) in dioxan (20ml) and 1N sodium hydroxide (5ml) was stirred at room temperature for 30 minutes. The solution was diluted with water (50ml) and washed with diethyl ether (50ml). The aqueous phase was acidified to pH 4 by
10 addition of 1N hydrochloric acid and extracted twice with diethyl ether (50ml). The combined organic extracts were washed with saturated brine (50ml), dried over magnesium sulphate and evaporated. The residual yellow gum was triturated with diethyl ether affording
15 the title compound (0.10g) as a cream solid, m.p. 163-165°C. [NMR {(CD₃)₂SO}:- 2.4 (s,3H), 5.3 (s,2H), 6.3 (s,1H), 6.9 (m,2H), 7.3 (m,3H), 7.5 (m,3H), 8.6 (dd,2H)].

20 EXAMPLE 41

(RS)-[5-(Benzoxazol-6-ylmethoxy)-2-cyano-3-fluorophenoxy]-(2-methylphenyl)acetic acid

- A solution of Reference Example 81 (0.35g) in dioxan (20ml) and 1N sodium hydroxide (3ml) was stirred at
25 room temperature for 1 hour then stood at ambient temperature for 18 hours. The reaction mixture was evaporated to low volume, diluted with water (50ml) and washed with diethyl ether (50ml). The aqueous phase was acidified to pH 6 by addition of 1N hydrochloric acid
30 and extracted three times with ethyl acetate (50ml). The combined organic extracts were washed with saturated brine (50ml), dried over magnesium sulphate and evaporated. The resulting orange solid was triturated with methanol affording the title compound
35 (0.24g) as an orange solid, m.p. 193-194°C. [Elemental

analysis:- C,65.93; H,4.0; N,5.9%. Calculated for
C₂₄H₁₇N₂O₅F•0.5CH₃OH:- C,66.63; H,4.24; N,6.25%].

EXAMPLE 42

5 (RS)-[5-(1,3-Benzodioxol-5-ylmethoxy)-2-cyano-3-
10 fluorophenoxy]-(2-methylphenyl)acetic acid

A solution of Reference Example 82 (1.42g) in dioxan
(20ml) and 1N sodium hydroxide (5ml) was stirred at
room temperature for 5 hours. The mixture was
10 evaporated to low volume and was diluted with water
(50ml) and washed with diethyl ether (50ml). The
aqueous phase was acidified to pH 6 by addition of 1N
hydrochloric acid and extracted once with diethyl ether
(50ml) and twice with ethyl acetate (50ml). The
15 combined organic extracts were washed with saturated
brine (50ml), dried over magnesium sulphate and
evaporated. The resulting colourless oil was triturated
with pentane affording the title compound (0.65g) as a
cream solid, m.p. 110-117°C. [NMR (CDCl₃):- 2.5 (s,3H),
20 4.9 (s,2H), 5.8 (s,1H), 6.0 (s,2H), 6.2 (m,1H), 6.4
(dd,1H), 6.8 (m,3H), 7.3 (m,3H), 7.6 (dd,1H)].

EXAMPLE 43

25 (RS)-[5-(Benzoxazol-5-yl)methoxy-2-cyanophenoxy]-(2-
30 methylphenyl)acetic acid

A solution of Reference Example 83 (0.12g) in dioxan
(10ml) was treated with 1N aqueous sodium hydroxide
(1ml) at room temperature. After 3 hours water was
added (20ml) and the mixture extracted with ethyl
30 acetate (20ml). The resulting aqueous layer was
acidified to pH 1 by addition of concentrated
hydrochloric acid and extracted three times with ethyl
acetate (25ml). The combined extracts were washed with
brine (25ml), dried over magnesium sulphate and
35 evaporated. The resulting residue was recrystallised
from ethyl acetate to give the title compound (80mg) as

a white solid, m.p. 189-191°C. [Elemental analysis:- C, 68.03; H, 4.49; N, 6.34%. Calculated for $C_{24}H_{18}N_2O_5 \cdot 0.5H_2O$:- C, 68.10; H, 4.52; N, 6.62%].

5 EXAMPLE 44

(RS)-(5-Benzoyloxy-2-cyanophenoxy)-(2-methylphenyl)acetic acid

A solution of Reference Example 85 (0.49g) in dioxan (10ml) was treated with 1N aqueous sodium hydroxide (3ml) at room temperature. After 30 minutes water was added (20ml) and the mixture extracted with ethyl acetate (20ml). The resulting aqueous layer was acidified to pH 1 by addition of concentrated hydrochloric acid and extracted three times with ethyl acetate (25ml). The combined extracts were washed with brine (25ml), dried over magnesium sulphate and evaporated. The resulting residue was purified by flash chromatography on silica eluting with a mixture of methanol and dichloromethane (1:19, v/v). Fractions homogenous in the required product were combined and evaporated. The resulting residue was triturated with diethyl ether and pentane to give the title compound (80mg) as a white solid, m.p. 128-130°C. [Elemental analysis:- C, 73.91; H, 5.26; N, 3.69%. Calculated:- C, 73.98; H, 5.13; N, 3.75%].

EXAMPLE 45

(RS)-[2-Cyano-5-(furan-3-ylmethoxy)phenoxy]-(2-methylphenyl)acetic acid

30 A solution of Reference Example 86 (1.01g) in dioxan (20ml) was treated with 1N aqueous sodium hydroxide (8ml) at room temperature. After 1 hour the resulting solution was evaporated, the residue diluted with water (10ml) and the pH adjusted to 2 by addition of 2N aqueous hydrochloric acid. The resulting mixture was extracted twice with ethyl acetate (20ml). The

combined extracts were washed with water, dried over magnesium sulphate, evaporated and the residue dissolved in 1N aqueous sodium hydroxide (30ml). The solution was washed twice with ether (40ml), adjusted to pH 1 by addition of 2N aqueous hydrochloric acid and extracted three times with ethyl acetate (30ml). The combined extracts were dried over magnesium sulphate and evaporated to give a colourless solid (0.29g). Recrystallisation from diisopropylether gave the title compound (0.18g) as colourless crystals, m.p. 141-143°C. [Elemental analysis:- C,69.5; H,4.81; N,4.12%. Calculated:- C,69.4; H,4.72; N,3.86%].

EXAMPLE 46

15 (RS)-N-Methoxy-[2-cyano-5-(3-thienylmethoxy)phenoxy]-(2-methylphenyl)acetamide

A solution of Example 6 (0.37g) in dichloromethane (10ml) was treated with oxalyl chloride (0.28g) and refluxed for 3 hours. After allowing to cool to room temperature the reaction mixture was concentrated. The resulting residue was re-dissolved in dichloromethane (15ml), treated with triethylamine (0.15ml) and methoxylamine hydrochloride (0.09g). After stirring at room temperature for 2 hours the reaction mixture was evaporated to dryness, diluted with water (50ml) and the mixture extracted twice with ethyl acetate (50ml). The combined organic extracts were washed with brine (30ml), dried over magnesium sulphate and evaporated. The resulting residue was purified by flash chromatography on silica eluting with a mixture of ethyl acetate and pentane (1:1, v/v). Fractions homogenous in the required product were combined and evaporated. The resulting residue was triturated with diethyl ether to give the title compound (0.1g) as a white solid,

m.p. 155-156°C. [Elemental analysis:- C,64.69; H,5.13; N,6.61%. Calculated:- C,64.69; H,4.94; N,6.86%].

REFERENCE EXAMPLE 1

5 4-Allyloxy-2-hydroxybenzaldehyde

A mixture of 2,4-dihydroxybenzaldehyde (15g), allyl bromide (9.6ml), potassium carbonate (15.4g), potassium iodide (18.5g) and tetra-n-butylammonium bromide (3.59g) in methyl ethyl ketone (200ml) was heated at
10 reflux for 1 hour. The reaction mixture was filtered and evaporated. The residue was partitioned between ethyl acetate (100ml) and water (100ml). The organic phase was evaporated and the residual oil (20g) purified by flash chromatography on silica eluting with
15 a mixture of pentane and ethyl acetate (95:5, v/v). Fractions homogenous in the required product were combined and evaporated to give the title compound (13.8g) as an oil.

20 REFERENCE EXAMPLE 2

4-Allyloxy-2-hydroxybenzaldehyde oxime

A mixture of Reference Example 1 (7.48g), hydroxylamine hydrochloride (3.32g) and pyridine (3.12ml) in ethanol (100ml) was heated at reflux for 1 hour. The reaction
25 mixture was evaporated and partitioned between ethyl acetate (100ml) and water (100ml). The organic phase was dried over magnesium sulphate and evaporated to low volume when pentane (80ml) was added to give the title compound (5.5g) as a colourless solid, m.p. 74-76°C.

30

REFERENCE EXAMPLE 3

2-Acetoxy-4-allyloxybenzonitrile

A mixture of Reference Example 2 (11.75g), sodium acetate (0.2g) and acetic anhydride (100ml) was heated
35 at reflux for 3 hours, cooled, carefully diluted with water (600ml) with stirring and extracted three times

with ethyl acetate (200ml). The combined extracts were washed with water (150ml), then with brine (150ml), dried over magnesium sulphate and evaporated. The residual pale orange oil was purified by flash
5 chromatography on silica eluting initially with a mixture of ethyl acetate and pentane (1:9, v/v) then with a mixture of ethyl acetate and pentane (15:85, v/v). Fractions homogenous in the required product were combined and evaporated to give the title compound
10 (13.7g) as a pale yellow oil.

REFERENCE EXAMPLE 4

4-Allyloxy-2-hydroxybenzonitrile

A solution of Reference Example 3 (13.7g) in a mixture
15 of methanol (15ml) and tetrahydrofuran (50ml) was treated, at room temperature, with a solution of potassium carbonate (8.72g) in water (100ml). After 2 hours, the reaction mixture was diluted with water (100ml), acidified to pH 1 by addition of 2N
20 hydrochloric acid and extracted three times with ethyl acetate (200ml). The combined organic extracts were washed with brine (200ml), dried over magnesium sulphate and evaporated. The resulting off-white solid was recrystallised from diisopropyl ether to give the
25 title compound (4.7g) as an off-white solid, m.p. 134-136°C.

REFERENCE EXAMPLE 5

Methyl (RS)-(5-allyloxy-2-cyanophenoxy)-(2-chlorophenyl)acetate
30

A mixture of Reference Example 4 (3.31g), Reference Example 10 (3.31g) and potassium carbonate (2.37g) in dimethylformamide (20ml) was stirred at ambient temperature for 2 hours. The reaction mixture was
35 diluted with water (30ml), acidified to pH 2 by addition of concentrated hydrochloric acid and

extracted three times with ethyl acetate (40ml). The combined extracts were washed with brine (30ml), dried over magnesium sulphate and evaporated. The residue was purified by flash chromatography on silica eluting with a mixture of ethyl acetate and pentane (1:4, v/v). Fractions homogenous in the required product were combined and evaporated to give the title compound (1.15g).

10 REFERENCE EXAMPLE 6

Methyl (RS)-(2-chlorophenyl)-[2-cyano-5-hydroxyphenoxy]acetate

A stirred solution of Reference Example 5 (1.15g) in a mixture of water (5ml) and ethanol (50ml) was treated with 1,4-diazabicyclo[2.2.2]octane (0.75g) and tris(triphenylphosphine)rhodium(I) chloride (0.3g). The reaction mixture was heated at reflux for 5 hours, evaporated to dryness and the residue partitioned between ethyl acetate (50ml) and 2N hydrochloric acid (50ml). The aqueous phase was extracted with ethyl acetate (25ml) and the combined organic phases were washed with brine, dried over magnesium sulphate and evaporated. The residue was purified by flash chromatography on silica eluting with a mixture of ethyl acetate and pentane (1:2, v/v). Fractions homogenous in the required product were combined and evaporated to give the title compound (0.62g) as a yellow oil.

30 REFERENCE EXAMPLE 7

Methyl (RS)-(2-chlorophenyl)-[2-cyano-5-(4-pyridylmethoxy)phenoxy]acetate

A solution of Reference Example 6 (0.63g) in acetone (25ml) was treated with potassium carbonate (0.28g) and 4-picolylchloride hydrochloride (0.36g) and then stirred at reflux temperature for 24 hours. The reaction mixture was evaporated and the residue

partitioned between ethyl acetate (100ml) and water (75ml). The organic phase was washed twice with 0.1N sodium hydroxide (20ml), then with brine (50ml), dried over magnesium sulphate and evaporated. The residual oil slowly solidified on standing. The solid was stirred with ethyl acetate (30ml), filtered and the filtrate evaporated to give the title compound (0.35g) as a plum coloured, waxy solid.

10 REFERENCE EXAMPLE 8

Methyl (RS)-[2-cyano-5-(3-thienylmethoxy)phenoxy]-phenylacetate

A solution of Reference Example 25 (1.0g) in dimethylformamide (14ml) was treated with sodium hydride (60% dispersion in mineral oil) and stirred at room temperature for 10 minutes. The solution was treated with methyl (RS)- α -bromophenylacetate (1.02g) and stirred at 25°C for 1 hour. The solution was diluted with water and extracted with ethyl acetate. The extract was washed with brine, dried and evaporated. The residue was washed with ether and recrystallised from a mixture of ethyl acetate and cyclohexane to give the title compound as a colourless solid (0.91g), m.p. 112-114°C.

25

REFERENCE EXAMPLE 9

Methyl 2-chlorophenylacetate

A solution of 2-chlorophenylacetic acid (10.0g) in methanol (100ml) containing 1 drop of concentrated sulphuric acid was heated at reflux for 2 hours. The reaction mixture was evaporated to half volume and partitioned between ethyl acetate (100ml) and water (100ml). The organic phase was dried over magnesium sulphate and evaporated to give the title compound (10.0g) as a colourless oil.

35

REFERENCE EXAMPLE 105 Methyl (RS)- α -bromo-(2-chlorophenyl)acetate

A mixture of Reference Example 9 (5.0g), N-bromosuccinimide (5.3g) and azobisisobutyronitrile (0.38g) in dry chloroform (50ml) was heated at reflux for 6 hours. The reaction mixture was washed three
10 times with water (30ml) and the organic phase dried over magnesium sulphate and evaporated. The residual oil was purified by flash chromatography on silica eluting with a mixture of ethyl acetate and pentane (5:95, v/v). Fractions homogenous in the required
15 product were combined and evaporated to give the title compound (4.0g) as an oil.

REFERENCE EXAMPLE 1120 Methyl (RS)-(2-chlorophenyl)-[2-cyano-5-(3-thienylmethoxy)phenoxy]acetate

A solution of Reference Example 25 (2.0g) in dimethylformamide (80ml) was treated with sodium hydride (0.22g, 60% dispersion in mineral oil) and stirred at ambient temperature for 10 minutes. The
25 solution was treated with Reference Example 10 (1.7g) and stirred at 25°C for 1 hour. The reaction mixture was partitioned between ethyl acetate (100ml) and water (100ml). The organic phase was washed twice with brine (100ml), dried over magnesium sulphate and evaporated.
30 The residual oil was triturated with pentane (50ml) to give the title compound (1.75g) as a colourless solid, m.p. 102-104°C. [Elemental analysis:- C, 60.97; H, 3.88; N, 3.31; S, 7.16%. Calculated:- C, 60.94; H, 3.89; N, 3.38; S, 7.74%].

REFERENCE EXAMPLE 124-(1,3-Benzodioxol-5-ylmethoxy)-2-hydroxybenzaldehyde

A mixture of 2,4-dihydroxybenzaldehyde (22.94g), 3,4-methylenedioxybenzyl chloride (34g), potassium carbonate (34.43g), potassium iodide (41.33g) and tetra-n-butylammonium bromide (6g) in methyl ethyl ketone was heated at reflux for 3 hours. The reaction mixture was filtered and evaporated. The residue was partitioned between ethyl acetate (400ml) and water (400ml) and the aqueous phase extracted twice with ethyl acetate (200ml). The combined organic phases were dried over magnesium sulphate and evaporated. The residual beige coloured solid was purified by flash chromatography on silica eluting initially with a mixture of pentane and ethyl acetate (95:5, v/v) then with a mixture of pentane and ethyl acetate (9:1, v/v) and finally with a mixture of pentane and ethyl acetate (85:15, v/v). Fractions homogenous in the required product were combined and evaporated to give the title compound (14.2g) as a white solid.

REFERENCE EXAMPLE 134-(1,3-Benzodioxol-5-ylmethoxy)-2-hydroxybenzaldehyde oxime

A mixture of Reference Example 12 (3.9g), hydroxylamine hydrochloride (0.99g) and pyridine (1.25ml) in ethanol (100ml) was heated at reflux for 1.5 hours. The reaction mixture was partitioned between ethyl acetate (100ml) and water (100ml) and the aqueous phase was extracted twice with ethyl acetate (100ml). The combined organic phases were washed with 1N hydrochloric acid (100ml), brine (100ml), dried over magnesium sulphate and evaporated to give the title compound (2.6g) as a white solid.

REFERENCE EXAMPLE 142-Acetoxy-4-(1,3-benzodioxol-5-ylmethoxy)benzonitrile

A mixture of Reference Example 13 (2.6g), sodium acetate (0.03g) and acetic anhydride (15ml) was heated at reflux for 3.5 hours, allowed to cool to room temperature and stood for 3 days. The reaction mixture was carefully diluted with water (250ml) with stirring and filtered. The insoluble material was recrystallised from a mixture of diisopropyl ether and ethyl acetate to give the title compound (1.52g) as a cream coloured solid.

REFERENCE EXAMPLE 154-(1,3-Benzodioxol-5-ylmethoxy)-2-hydroxybenzonitrile

Method A: A solution of Reference Example 14 (1.5g) in a mixture of methanol (15ml) and tetrahydrofuran (7ml) was treated, at room temperature, with a solution of potassium carbonate (0.66g) in water (10ml). The solution slowly turned reddish-brown and after 1 hour the reaction mixture was diluted with water (30ml) and extracted three times with ethyl acetate (75ml). The combined organic extracts were washed with brine (30ml), dried over magnesium sulphate and evaporated to give the title compound (1.34g) as a sand coloured solid.

Method B: A stirred suspension of Reference Example 12 (845.0g) in ethanol (7770ml) was treated with a solution of hydroxylamine-O-sulphonic acid (470.7g) in demineralised water (1110ml). The reaction mixture was stirred at 25-30°C for about 1 hour forming a clear solution. The solution was cooled to about 5°C then aqueous sodium hydroxide (1550ml; 9.1N) was added over about 3 hours keeping the temperature between 5°C and 15°C. The mixture was then stirred at 5°-15°C until the

reaction was complete by thin layer chromatography (about 1 - 1.5 hours). Keeping the temperature below 30°C, the pH of the mixture was adjusted to 1 - 2 by addition of concentrated hydrochloric acid. The mixture was diluted with demineralised water (3900ml) and stirred for 30 minutes at 25-30°C. The product was collected, washed with demineralised water (3900ml) and dried by suction then at 45-50°C/ 500 to 750Torr to give the title compound (760.0g).

10

REFERENCE EXAMPLE 16Methyl (RS)-[5-(1,3-benzodioxol-5-ylmethoxy)-2-cyano-phenoxy]-phenylacetate

A mixture of Reference Example 15 (1.3g), methyl (RS)- α -bromophenylacetate (1.22g) and potassium carbonate (1.0g) in dimethylformamide (10ml) was stirred at ambient temperature for 2 hours. Water (30ml) was added and the solution acidified to pH 2 by addition of concentrated hydrochloric acid. The mixture was extracted three times with ethyl acetate (30ml) and the combined extracts were washed with brine (30ml), dried over magnesium sulphate and evaporated. On standing the title compound (0.77g) was slowly deposited as a white solid.

25

REFERENCE EXAMPLE 17Methyl 2-trifluoromethylphenylacetate

A solution of 2-trifluoromethylphenylacetic acid (5.0g) in methanol (30ml) containing 5 drops of concentrated sulphuric acid was heated at reflux for 2 hours. The reaction mixture was concentrated, diluted with ethyl acetate (100ml), washed with 1N sodium hydroxide (25ml) then with brine (25ml), dried over magnesium sulphate and evaporated to give the title compound (5.04g) as a colourless oil.

35

REFERENCE EXAMPLE 18Methyl (RS)- α -bromo-(2-trifluoromethylphenyl)acetate

A mixture of Reference Example 17 (5.0g), N-bromosuccinimide (4.22g) and azobisisobutyronitrile (0.33g) in dry chloroform (40ml) was heated at reflux for 18 hours. The reaction mixture was washed three times with water (25ml) and the organic phase dried over magnesium sulphate and evaporated. The residual yellow oil was purified by flash chromatography on silica eluting with a mixture of ethyl acetate and pentane (1:3, v/v). Fractions homogenous in the required product were combined and evaporated to give the title compound (5.8g) as a yellow oil.

REFERENCE EXAMPLE 19Methyl (RS)-[5-(1,3-benzodioxol-5-ylmethoxy)-2-cyanophenoxy]-(2-trifluoromethylphenyl)acetate

A mixture of Reference Example 15 (0.5g), Reference Example 18 (0.58g) and potassium carbonate (0.38g) in dimethylformamide (5ml) was stirred at ambient temperature for 1.5 hours. The reaction mixture was diluted with water (20ml), acidified to pH 1 by addition of concentrated hydrochloric acid and extracted three times with ethyl acetate (20ml). The combined extracts were washed with brine (20ml), dried over magnesium sulphate and evaporated. The residual yellow semi-solid was triturated with ether to give the title compound (0.36g) as a pale beige coloured solid.

REFERENCE EXAMPLE 20Methyl (RS)- α -hydroxy-(2-methylphenyl)acetate

A solution of (RS)- α -hydroxy-(2-methylphenyl)acetic acid (3.6g) in methanol (80ml) containing 2 drops of concentrated sulphuric acid was heated at reflux for 2

hours. The reaction mixture was concentrated and the residual oil partitioned between ethyl acetate and water. The organic phase was washed with water, dried over magnesium sulphate and evaporated to give the
5 title compound (2.5g) as a colourless oil.

REFERENCE EXAMPLE 21

Methyl (RS)- α -bromo-(2-methylphenyl)acetate

Method A: To a stirred solution of Reference Example 20
10 (2.0g) in dry dichloromethane (30ml) at 0°C was added triphenylphosphine (0.727g) and carbon tetrabromide (0.92g). The reaction mixture was stirred at ambient temperature for 3 hours and evaporated. The resulting oil was dissolved in ether and the solution filtered
15 through a pad of silica washing the silica with ether. The combined filtrate and washings were evaporated and the residual oil was purified by flash chromatography on silica eluting with a mixture of ethyl acetate and pentane (1:4, v/v). Fractions homogenous in the
20 required product were combined and evaporated to give the title compound (1.8g) as a colourless oil.

Method B: A stirred solution of Reference Example 20 (63.2g) in dry toluene (250ml) at ambient temperature was treated with thionyl bromide (27ml) and the mixture
25 stood at ambient temperature for 3 days. The reaction mixture was washed with sodium bicarbonate solution until the washings were neutral, washed twice with brine (100ml), dried over magnesium sulphate and evaporated affording the title compound (74.5g) as a
30 pale yellow oil.

REFERENCE EXAMPLE 22

Methyl (RS)-[2-cyano-5-(3-thienylmethoxy)phenoxy]-(2-methylphenyl)acetate

35 A solution of Reference Example 25 (0.7g) in dimethylformamide (80ml) was treated with sodium

hydride (0.11g, 60% dispersion in mineral oil) and stirred at ambient temperature for 40 minutes. The solution was treated with Reference Example 21 (0.726g) and stirred at ambient temperature for 2 hours. The reaction mixture was concentrated and partitioned between ethyl acetate and water. The organic phase was washed with brine, dried over magnesium sulphate and evaporated. The residual oil was purified by flash chromatography on silica eluting with a mixture of ethyl acetate and pentane (1:4, v/v). Fractions homogenous in the required product were combined and evaporated, and the residual solid triturated with a mixture of pentane and ether to give the title compound (0.6g) as a colourless solid, m.p. 102-104°C.

REFERENCE EXAMPLE 23

Methyl (RS)-[5-(1,3-benzodioxol-5-ylmethoxy)-2-cyanophenoxy]-(2-chlorophenyl)acetate

A mixture of Reference Example 15 (1.5g), Reference Example 10 (1.62g) and potassium carbonate (1.16g) in dimethylformamide (15ml) was stirred at ambient temperature for 1.5 hours. The reaction mixture was diluted with water (30ml), acidified to pH 2 by addition of concentrated hydrochloric acid and extracted three times with ethyl acetate (40ml). The combined extracts were washed with brine (30ml), dried over magnesium sulphate and evaporated. The residual yellow semi-solid was purified by flash chromatography on silica eluting initially with a mixture of ethyl acetate and pentane (1:4, v/v), then with a mixture of ethyl acetate and pentane (3:10, v/v). Fractions homogenous in the required product were combined and evaporated to give the title compound (0.36g) as a colourless oil which slowly solidified on standing.

REFERENCE EXAMPLE 242-Hydroxy-4-(3-thienylmethoxy)benzaldehyde

A stirred solution of 2,4-dihydroxybenzaldehyde (31.8g) in dry dimethylformamide (150ml) at ambient temperature was treated with sodium hydride (11.96g; 60% dispersion in mineral oil), portionwise, during 30 minutes. After a further period of 15 minutes, the mixture was treated, dropwise, with a solution of 3-chloromethylthiophene (35g) in dimethylformamide (50ml). The mixture was stirred at 70°C for 2 hours, cooled and the solvent evaporated. The residue was partitioned between ethyl acetate (200ml) and 0.5N hydrochloric acid (200ml) and the aqueous layer was extracted twice with ethyl acetate (100ml). The combined organic phases were washed with brine (100ml), dried over magnesium sulphate, and evaporated. The residue was subjected to flash chromatography on silica eluting with a mixture of ethyl acetate and pentane (1:4, v/v), to give a colourless oil, which crystallised on standing. This solid was recrystallised from diisopropyl ether, to give the title compound (8g) as a white solid.

REFERENCE EXAMPLE 252-Hydroxy-4-(3-thienylmethoxy)benzonitrile

A mixture of Reference Example 24 (7.7g), nitroethane (4.74ml), sodium acetate (5.4g) and glacial acetic acid (6.6ml) was heated at reflux for 14 hours. The mixture was then cooled, diluted with water (50ml) and extracted three times with ethyl acetate (50ml). The combined extracts were washed with saturated aqueous sodium bicarbonate solution (50ml), dried over magnesium sulphate and evaporated. The residue was subjected to flash chromatography on silica eluting with a mixture of ethyl acetate and

pentane (3:7, v/v), to give the title compound (7.6g) as a pale yellow solid.

REFERENCE EXAMPLE 26

5 Methyl 2-bromophenylacetate

A solution of 2-bromophenylacetic acid (5.6g) in methanol (80ml) containing 6 drops of concentrated sulphuric acid was heated at reflux for 12 hours. The reaction mixture was concentrated, dissolved in ether
10 (100ml) and washed with water. The ether solution was dried over magnesium sulphate and evaporated to give the title compound (5.8g) as a light orange oil.

REFERENCE EXAMPLE 27

15 Methyl (RS)- α -bromo-(2-bromophenyl)acetate

A mixture of Reference Example 26 (2.29g), N-bromosuccinimide (1.78g) and azobisisobutyronitrile (0.145g) in dry chloroform (25ml) was heated at reflux for 6 hours. The reaction mixture was washed with brine.
20 and concentrated to give the title compound (2.9g) as an orange oil.

REFERENCE EXAMPLE 28

25 Methyl (RS)-(2-bromophenyl)-[2-cyano-5-(3-thienylmethoxy)phenoxy]acetate

A solution of Reference Example 25 (0.693g) in dimethylformamide (10ml) was treated with sodium hydride (0.12g, 60% dispersion in mineral oil) and stirred at ambient temperature for 15 minutes. The
30 solution was treated with Reference Example 27 (1.7g) and stirred at 25°C for 1 hour. The reaction mixture was diluted with water (60ml) and extracted with ethyl acetate. The organic extracts were washed with water, then with brine, dried over magnesium sulphate and
35 evaporated. The residual oil was purified by flash chromatography on silica eluting with a mixture of

pentane and ether (3:2, v/v). Fractions homogenous in the required product were combined and evaporated. The residue was triturated with ether to give the title compound (0.52g) as a white solid, m.p. 92-95°C.

- 5 [Elemental analysis:- C,55.17; H,3.58; N,3.10; S,7.37%.
Calculated:- C,55.03; H,3.52; N,3.06; S,6.99%].

REFERENCE EXAMPLE 29

Methyl 3-chlorophenylacetate

- 10 A solution of 3-chlorophenylacetic acid (10.0g) in methanol (80ml) containing 2 drops of concentrated sulphuric acid was heated at reflux for 3 hours. The reaction mixture was concentrated and partitioned between ethyl acetate (100ml) and water (100ml). The
15 organic phase was dried over magnesium sulphate and evaporated to give the title compound (9.8g) as a colourless oil.

REFERENCE EXAMPLE 30

- 20 Methyl (RS)- α -bromo-(3-chlorophenyl)acetate

- A mixture of Reference Example 29 (5.0g), N-bromosuccinimide (5.3g) and azobisisobutyronitrile (0.38g) in dry chloroform (50ml) was heated at reflux for 6 hours. The reaction mixture was washed four times
25 with water (50ml) and the organic phase dried over magnesium sulphate and evaporated. The residual oil was purified by flash chromatography on silica eluting with a mixture of ethyl acetate and pentane (5:95, v/v). Fractions homogenous in the required product were
30 combined and evaporated to give the title compound (4.3g) as an oil.

REFERENCE EXAMPLE 31

- Methyl (RS)-(3-chlorophenyl)-[2-cyano-5-(3-thienylmethoxy)phenoxy]acetate
35

A solution of Reference Example 25 (2.0g) in dimethylformamide (80ml) was treated with sodium hydride (0.22g, 60% dispersion in mineral oil) and stirred at ambient temperature for 1 hour. The solution
5 was treated with Reference Example 30 (1.7g) and stirred at 25°C for 2 hours. The reaction mixture was concentrated and partitioned between ethyl acetate (200ml) and water (200ml). The organic phase was washed
10 twice with water (50ml) then with brine (50ml), dried over magnesium sulphate and evaporated. The residual oil was purified by flash chromatography on silica eluting with a mixture of ethyl acetate and pentane (1:4, v/v). Fractions homogenous in the required
product were combined and evaporated to give the title
15 compound (1.0g).

REFERENCE EXAMPLE 32

2-Fluoro-4-(4-pyridylmethoxy)benzonitrile

A mixture of 2-fluoro-4-hydroxybenzonitrile (10.96g; S.
20 M. Kelly, Helv. Chim. Acta 1984, volume 67, p1572-1579), potassium carbonate (53.2g), potassium iodide (6.64g), tetra-n-butylammonium bromide (0.4g) and 4-picolyl chloride (14.4g) in methyl ethyl ketone (600ml) was stirred at reflux for 3 hours. The reaction mixture
25 was filtered and the insoluble material washed with methyl ethyl ketone. The combined filtrate plus washings were evaporated and the residue partitioned between ethyl acetate (300ml) and water (150ml). The aqueous phase was extracted twice with ethyl acetate
30 (100ml) and the combined ethyl acetate solutions washed with brine (100ml), dried over magnesium sulphate and evaporated. The residue was recrystallised from a mixture of ethyl acetate and pentane to give the title
compound (11.5g) as a plum coloured solid, m.p. 132-
35 133°C.

REFERENCE EXAMPLE 33

Methyl (RS)-[2-cyano-5-(3-thienylmethoxy)phenoxy]-(2-fluorophenyl)acetate

- A solution of Reference Example 25 (0.693g) in
5 dimethylformamide (10ml) was treated with sodium
hydride (0.12g, 60% dispersion in mineral oil) and
stirred at ambient temperature for 30 minutes. The
solution was treated with methyl (RS)- α -bromo-(2-
10 fluorophenyl)acetate (1.8g) and stirred at ambient
temperature for 2 hours. The reaction mixture was
concentrated and partitioned between ethyl acetate and
water. The organic phase was washed with brine, dried
over magnesium sulphate and evaporated. The residual
15 brown oil (1.8g) was purified by flash chromatography
on silica eluting with dichloromethane. Fractions
homogenous in the required product were combined and
evaporated. The residual solid was triturated with a
mixture of pentane and ether affording the title
compound (0.75g) as a white solid, m.p. 104-106°C.
20 [Elemental analysis:- C,63.71; H,4.09; N,3.8; S,7.8%.
Calculated:- C,63.47; H,4.06; N,3.53; S,8.07%]

REFERENCE EXAMPLE 34

Methyl (RS)-[2-cyano-5-(3-thienylmethoxy)phenoxy]-(2-
25 trifluoromethylphenyl)acetate

- A solution Reference Example 25 (1.5g) in
dimethylformamide (100ml) was treated with sodium
hydride (0.24g, 60% dispersion in mineral oil) and
stirred at ambient temperature for 30 minutes. The
30 solution was treated with Reference Example 18 (1.8g)
and stirred at ambient temperature for 2 hours. The
reaction mixture was concentrated and partitioned
between ethyl acetate (100ml) and water (100ml). The
organic phase was washed with brine, dried over
35 magnesium sulphate and evaporated. The residual oil
(0.98g) was purified by flash chromatography on silica

eluting with a mixture of ethyl acetate and pentane (1:4, v/v). Fractions homogenous in the required product were combined, evaporated and the residual solid triturated with a mixture of pentane and ether
5 affording the title compound (0.8g) as a colourless solid, m.p. 104-108°C.

REFERENCE EXAMPLE 35

Methyl (RS)-(2-chlorophenyl)-[2-cyano-5-(pyridazin-4-ylmethoxy)phenoxy]acetate
10

A stirred mixture of Reference Example 6 (0.481g) and 4-chloromethylpyridazine hydrochloride (0.25g) in dimethylformamide (6ml) at 5°C was treated with sodium hydride (0.121g; 60% dispersion in mineral oil). After
15 stirring at 5°C for 1 hour the reaction mixture was allowed to warm to room temperature, stirring was continued for a further 2 hours at room temperature then at 60°C for 4 hours. The reaction mixture was evaporated and the residual oil partitioned between
20 ethyl acetate (50ml) and water (20ml). The aqueous phase was extracted three times with ethyl acetate. The combined organic phases were washed with brine (5ml), dried over magnesium sulphate and evaporated. The residual oil (700mg) was purified by flash
25 chromatography on silica eluting with a mixture of dichloromethane and methanol (99:1, v/v). Fractions homogenous in the required product were combined and evaporated affording the title compound (0.2g) as a white solid, m.p. 136-138°C. [Elemental analysis:-
30 C, 61.45; H, 3.92; N, 10.11%. Calculated:- C, 61.54; H, 3.93; N, 10.25%].

REFERENCE EXAMPLE 36

4-(1,3-Benzodioxol-5-ylmethoxy)-2-fluorobenzonitrile

A mixture of 2-fluoro-4-hydroxybenzonitrile (S.M. Kelly, Helv.Chim.Acta. 1984, Volume 67, P.1572-1579) (30g), potassium carbonate (45.36g) and 3,4-methylenedioxybenzyl chloride (42.65g) in
5 dimethylformamide (500ml) was stirred at 90°C for 2 hours. The reaction mixture was filtered and the filtrate evaporated. The residue was stirred with ethyl acetate (500ml) and filtered affording the title compound (32.1g) as a cream coloured solid, m.p. 139-
10 140°C.

REFERENCE EXAMPLE 37

Methyl (RS)-(2-chlorophenyl)-[2-cyano-5-(isothiazol-4-ylmethoxy)phenoxy]acetate

15 A stirred solution of triphenylphosphine (2.2g) in tetrahydrofuran at -5°C was treated dropwise with diisopropyl azodicarboxylate (1.65ml). After stirring - 5°C for 30 minutes a solution of Reference Example 6 (1.5g) in dry tetrahydrofuran (5ml) was added, followed
20 by a solution of 4-hydroxymethylisothiazole (0.5g) resulting in the formation of a red solution. The reaction mixture was allowed to warm to room temperature, then stood at room temperature for 18 hours and evaporated. The residue was treated with
25 ethyl acetate (40ml) and the organic phase washed twice with water (20ml), then with brine (20ml), dried over magnesium sulphate and evaporated. The residual amber coloured oil (7g) was purified by flash chromatography on silica eluting with a mixture of ether and pentane
30 (1:1, v/v). Fractions homogenous in the required product were combined and evaporated. The resulting yellow gum (1.44g) was triturated with ether (25ml) affording the title compound (0.44g) as a white solid.

REFERENCE EXAMPLE 38Methyl (RS)-[2-cyano-5-(3-pyridylmethoxy)phenoxy]-phenylacetate

A mixture of Reference Example 41 (0.5g), methyl (RS)-
5 α -bromophenylacetate (0.55g) and potassium carbonate
(0.5g) in dimethylformamide (25ml) was stirred at
ambient temperature for 1.5 hours. The reaction mixture
was diluted with water, the pH of the solution adjusted
to 4-5 by addition of 2N hydrochloric acid and the
10 mixture extracted with ethyl acetate. The organic
extracts were washed with brine, dried over magnesium
sulphate and evaporated. The residual oil was purified
by flash chromatography on silica eluting with a
mixture of pentane and ethyl acetate (3:1, v/v).
15 Fractions homogenous in the required product were
combined and evaporated affording the title compound
(0.52g) as a white solid.

REFERENCE EXAMPLE 3920 2-Hydroxy-4-(3-pyridylmethoxy)benzaldehyde

A mixture of 2,4-dihydroxybenzaldehyde (25g), 3-picolyl
chloride hydrochloride (38.2g), potassium carbonate
(91g), potassium iodide (0.5g) and tetra-n-
butylammonium bromide (0.5g) in methyl ethyl ketone
25 (1000ml) was heated at reflux for 4 hours. The reaction
mixture was filtered and evaporated. The residue was
partitioned between ethyl acetate and dilute acetic
acid. The organic phase was washed with water, dried
over magnesium sulphate and evaporated. The residue was
30 purified by flash chromatography on silica eluting
initially with a mixture of pentane and ethyl acetate
(3:1, v/v) then with a mixture of pentane and ethyl
acetate (1:1, v/v) and finally with a mixture of
pentane and ethyl acetate (85:15, v/v). Fractions
35 homogenous in the required product were combined and

evaporated affording the title compound (5g) as an off-white solid.

REFERENCE EXAMPLE 40

5 2-Hydroxy-4-(3-pyridylmethoxy)benzaldehyde oxime

A mixture of Reference Example 39 (5g), hydroxylamine hydrochloride (1.72g) and pyridine (2ml) in ethanol (100ml) was heated at reflux for 1.5 hours. The reaction mixture was evaporated and the residual solid
10 triturated with diethyl ether affording the title compound (2.7g).

REFERENCE EXAMPLE 41

2-Hydroxy-4-(3-pyridylmethoxy)benzonitrile

15 A mixture of Reference Example 40 (2.5g), sodium acetate (0.03g) and acetic anhydride (10ml) was heated at reflux for 1.5 hours. The cooled reaction mixture was carefully diluted with water (250ml) with stirring and filtered. The resulting brown oil was extracted
20 with ethyl acetate. Evaporation of the organic extracts and crystallisation from isopropanol afforded 2-acetoxy-4-(3-pyridylmethoxy)benzonitrile (2.15g) which was dissolved in a mixture of methanol (10ml) and tetrahydrofuran (7.5ml) and treated, at room
25 temperature, with a solution of potassium carbonate (1g) in water (10ml). After 2 hours the reaction mixture was diluted with water (50ml) and the pH of the mixture was adjusted to 4 by addition of 2N
30 hydrochloric acid. The mixture was extracted with ethyl acetate. The organic extracts were washed with brine, dried over magnesium sulphate and evaporated affording the title compound (1.12g) as a white solid.

REFERENCE EXAMPLE 42

35 Methyl (RS)-[2-formyl-5-(3-thienylmethoxy)phenoxy]-phenylacetate

A mixture of Reference Example 24 (3.00g), methyl (RS)- α -bromophenylacetate (3.23g) and potassium carbonate (2.65g) in dimethylformamide (50ml) was stirred at 25°C for 1.5 hours. The reaction mixture was treated with water (50ml), acidified to pH 3 by addition of concentrated hydrochloric acid and extracted five times with ethyl acetate (100ml). The combined extracts were washed with brine (100ml), dried and evaporated. The residual cream solid was washed with diethyl ether affording the title compound (2.80g) as a white solid.

REFERENCE EXAMPLE 43

Methyl (RS)-(2-chlorophenyl)-[2-cyano-3-fluoro-5-(3-thienylmethoxy)phenoxy]acetate

A solution of Reference Example 44 (0.97g) in dry tetrahydrofuran (40ml) was treated with sodium hydride (0.17g, 60% dispersion in mineral oil). After stirring at room temperature for 30 minutes the reaction mixture was treated with a solution of Reference Example 10 (1.12g) in dry dimethylformamide (10ml) and stirring was continued at ambient temperature for 2 hours. The reaction mixture was diluted with water (100ml), the pH of the solution was adjusted to 3 by addition of 1N hydrochloric acid and extracted four times with ethyl acetate (50ml). The combined organic extracts were washed with brine (50ml), dried over magnesium sulphate and evaporated. The residual dark yellow oil was purified by flash chromatography on silica eluting with a mixture of light petroleum and ethyl acetate (4:1, v/v). Fractions homogenous in the required product were combined and evaporated affording the title compound (0.95g) as a white solid, m.p. 143-144°C.

REFERENCE EXAMPLE 44

2-Fluoro-6-hydroxy-4-(3-thienylmethoxy)benzonitrile

A mixture of Reference Example 45 (1g), nitroethane (0.6g), sodium acetate (0.66g) and glacial acetic acid (1ml) was heated at reflux for 2 hours. The reaction mixture was cooled to ambient temperature, water (50ml) was added and the mixture extracted three times with ethyl acetate (50ml). The combined organic extracts were washed with saturated brine (50ml), dried over magnesium sulphate and evaporated. The residual brown oil was purified by flash chromatography on silica eluting with a mixture of ethyl acetate and pentane (1:2, v/v). Fractions homogeneous in the required product were combined and evaporated to give the title compound (250mg) as a yellow solid.

15 REFERENCE EXAMPLE 45

2-Fluoro-6-hydroxy-4-(3-thienylmethoxy)benzaldehyde

Sodium hydride (0.52g, 60% dispersion in mineral oil) was added portionwise over 30 minutes to a solution of Reference Example 46 (2g) in dimethylformamide (50ml) at 0°C. After stirring at 0°C for 30 minutes a solution of 3-chloromethylthiophene (1.72g) in dimethylformamide (50ml) was added and the mixture stirred at 60°C for 16 hours. The reaction mixture was concentrated and the residue partitioned between diethyl ether (50ml) and water (50ml). The aqueous phase was extracted four times with diethyl ether (50ml) and the combined organic extracts washed with brine (50ml), dried over magnesium sulphate and evaporated. The residue was purified by flash chromatography on silica eluting with a mixture of ethyl acetate and pentane (1:4, v/v). Fractions homogeneous in the required product were combined and evaporated to give a pale yellow solid which was triturated with diisopropyl ether to give the title compound (1.1g) as a yellow solid.

REFERENCE EXAMPLE 462,4-Dihydroxy-6-fluorobenzaldehyde

Dimethylformamide (12.7g) was added to vigorously stirred phosphorous oxychloride (14.4g) at 0°C. The reaction mixture was stirred at this temperature for 30 minutes, then 3,5-dihydroxyfluorobenzene (6g) was added. The sticky red syrup was allowed to warm to room temperature and stirred for 2 hours, then left to stand for 14 hours. Water (100ml) was added and the mixture extracted three times with ethyl acetate (100ml). The combined organic extracts were washed with brine (100ml), dried over magnesium sulphate and evaporated. The residue was purified by flash chromatography on silica eluting with a mixture of ethyl acetate and pentane (1:2, v/v). Fractions homogeneous in the required product were combined and evaporated to give an orange solid which was triturated with ethyl acetate to give the title compound (2g) as a yellow solid.

REFERENCE EXAMPLE 47Methyl (RS)-[5-(benzoxazol-6-ylmethoxy)-2-cyanophenoxy]-(2-chlorophenyl)acetate

A mixture of Reference Example 6 (3.24g), Reference Example 48 (2.17g) and potassium carbonate (1.41g) in dry dimethylformamide (60ml) was stirred at room temperature under nitrogen for 18 hours. The reaction mixture was evaporated, water (60ml) was added and the solution extracted three times with ethyl acetate (60ml). The combined extracts were washed twice with water (40ml), with brine (50ml), dried over magnesium sulphate and evaporated. The residual material was purified by flash chromatography on silica eluting with a mixture of diethyl ether and pentane (1:1, v/v). Fractions homogenous in the required product were combined and evaporated. The residue was triturated twice with pentane (10ml) affording the title compound

(1.49g) as a white solid, m.p. 157-159°C. [Elemental analysis:- C,64.9; H,3.96; N,6.33; Cl,7.77%. Calculated:- C,64.22; H,3.82; N,6.24; Cl,7.89%].

5 REFERENCE EXAMPLE 48

6-Bromomethylbenzoxazole

A mixture of 6-methylbenzoxazole (5.0g; J.T.Gupton, K.F.Correia and B.S.Foster, Synthetic Communications, 1986, 16, 365), N-bromosuccinimide (7.0g) and
10 azobisisobutyronitrile (0.55g) in dry chloroform (100ml) was heated at reflux for 1 hour. The cooled reaction mixture was washed three times with water (40ml), dried over magnesium sulphate and evaporated. The residual orange coloured viscous solid was
15 trituated twice with pentane (50ml) affording the title compound (6.20g) as a buff coloured solid, m.p. 52-56°C.

REFERENCE EXAMPLE 49

20 Ethyl (RS)- α -hydroxy-[2-(3-methyl)thienyl]acetate

A stirred solution of ethyl 2-[2-(3-methyl)thienyl]-2-oxoacetate (5.5g) in tetrahydrofuran (50ml) and water (2ml) was cooled in an acetone/ice bath and treated with sodium borohydride (0.45g). After stirring in the
25 ice bath for about 1 hour a little acetone was added to destroy excess borohydride, and the mixture evaporated to low bulk. The residue was partitioned between ethyl acetate and 0.1N hydrochloric acid. The organic phase was washed with 5% aqueous sodium bicarbonate solution,
30 then with water, dried over magnesium sulphate and evaporated. The residue was purified by passage down a short bed of silica, eluting initially with a mixture of dichloromethane and cyclohexane (1:1, v/v) then with dichloromethane. Fractions homogenous in the required

product were combined and evaporated affording the title compound (1.14g) as a colourless mobile oil.

REFERENCE EXAMPLE 50

5 2-Fluoro-4-(thiazol-5-ylmethoxy)benzonitrile

Diisopropylazodicarboxylate (4.0g) was dissolved in a little anhydrous tetrahydrofuran (about 10ml) and added dropwise to a stirred solution of triphenylphosphine (5.2g) in anhydrous tetrahydrofuran (150ml) at 0°C

10 under nitrogen. After stirring at 0°C for 15 minutes, during which time a white precipitate formed, a mixture of 2-fluoro-4-hydroxybenzonitrile (S.M. Kelly, Helv.Chim.Acta. 1984, Volume 67, P.1572-1579) (2.0g) and thiazole-5-methanol (2.3g) in anhydrous
15 tetrahydrofuran (20ml) was added dropwise whilst maintaining the temperature at or below 5°C. The reaction mixture was stirred in the cooling bath for a further 2 hours then allowed to warm slowly to room temperature. After standing at room temperature
20 overnight the reaction mixture was partitioned between ethyl acetate (200ml) and saturated aqueous ammonium chloride solution (200ml). The layers were separated and the organic phase washed with water (100ml), dried over magnesium sulphate and evaporated. The residue was
25 purified by flash chromatography on silica eluting with a mixture of ethyl acetate and cyclohexane (1:1, v/v). Fractions homogenous in the required product were combined and evaporated affording the title compound as a pale yellow solid (2.0g).

30

REFERENCE EXAMPLE 51

Methyl (RS)-(2-chlorophenyl)-[2-cyano-3-fluoro-5-(4-pyridylmethoxy)phenoxy]acetate

A mixture of Reference Example 52 (0.6g), 4-
35 picolylchloride hydrochloride (0.32g), potassium

carbonate (1.24g), potassium iodide ((0.15g) and tetra-
n-butylammonium bromide (20mg) in methyl ethyl ketone
(30ml) was heated to reflux and maintained for 1 hour.
The mixture was evaporated to dryness and partitioned
5 between 10% acetic acid (50ml) and ethyl acetate
(50ml). The organic layer was separated and the aqueous
layer extracted twice with ethyl acetate (250ml). The
combined organic extracts were washed with saturated
brine (50ml), dried over magnesium sulphate and
10 evaporated affording the title compound (0.72g) as a
brown oil, which was used without further purification.

REFERENCE EXAMPLE 52

Methyl (RS)-(2-chlorophenyl)-[2-cyano-3-fluoro-5-
15 hydroxyphenoxy]acetate

Nitrogen was bubbled through a solution of Reference
Example 53 (0.66g) in ethanol (60ml) and water (6ml)
for 20 minutes. Diazabicyclo[2,2,2]octane (0.04g) and
tris(triphenylphosphine)rhodium (I) chloride (0.125g)
20 were added and the mixture heated to reflux. After
refluxing for 4.5 hours the reaction mixture was cooled
to room temperature and partitioned between 1N
hydrochloric acid (50ml) and ethyl acetate (50ml). The
organic layer was separated and the aqueous layer
25 extracted twice with ethyl acetate (50ml). The combined
organic extracts were washed with saturated brine
(50ml), dried over magnesium sulphate and evaporated.
The residual yellow oil was purified by flash
chromatography on silica eluting with a mixture of
30 ethyl acetate and petroleum ether (33:67, v/v).
Fractions homogenous in the required product were
combined and evaporated affording the title compound
(0.6g) as a yellow oil.

35 REFERENCE EXAMPLE 53

Methyl (RS)-[5-allyloxy-2-cyano-3-fluorophenoxy]-(2-
chlorophenyl)acetate

A solution of Reference Example 54 (0.52g) in dry dimethylformamide (30ml) under nitrogen was treated with sodium hydride (0.12g, 60% dispersion in mineral oil). The mixture was stirred at room temperature for 20 minutes then treated dropwise with a solution of Reference Example 10 (0.78g) in dry dimethylformamide (10ml). The resulting solution was stirred at room temperature for 1 hour, quenched with water (50ml), the solution acidified to pH 1 by addition of 1N hydrochloric acid and extracted four times with diethyl ether (40ml). The combined organic extracts were washed with saturated brine (50ml), dried over magnesium sulphate and evaporated. The residual red oil was purified by flash chromatography on silica eluting with a mixture of ethyl acetate and petroleum ether (1:5, v/v). Fractions homogenous in the required product were combined and evaporated affording the title compound (1.01g) as a colourless foam.

20 REFERENCE EXAMPLE 54

4-Allyloxy-2-fluoro-6-hydroxybenzonitrile

A mixture of Reference Example 55 (1.1g) in methanol (20ml) and 10% potassium carbonate solution (13.5ml) was stirred at room temperature for 30 minutes then evaporated to low bulk. The residue was partitioned between water (50ml) and pentane (50ml). The aqueous layer was acidified to pH 1 by addition of 1N hydrochloric acid and extracted three times with diethyl ether (40ml). The combined organic extracts were washed with saturated brine (50ml), dried over magnesium sulphate and evaporated. The residual pale pink solid was triturated with pentane affording the title compound (0.87g) as a pale pink solid, m.p. 153-155°C.

REFERENCE EXAMPLE 552-Acetoxy-4-allyloxy-6-fluorobenzonitrile

A mixture of Reference Example 56 (0.96g), sodium acetate (20mg) and acetic anhydride was heated at reflux for 1.5 hours. The reaction mixture was allowed to cool to room temperature, diluted with water (50ml) and extracted four times with diethyl ether (30ml). The combined organic extracts were washed with saturated brine (50ml), dried over magnesium sulphate and evaporated affording the title compound (1.13g) as a red/pink oil which was used without further purification.

REFERENCE EXAMPLE 564-Allyloxy-2-fluoro-6-hydroxybenzaloxime

A mixture of Reference Example 57 (0.92g), hydroxylamine hydrochloride (0.33g) and pyridine (0.37g) in ethanol (50ml) was stirred at reflux for 1 hour. The mixture was cooled to room temperature and concentrated to low volume and partitioned between water (50ml) and diethyl ether (50ml). The aqueous layer was extracted twice with diethyl ether (50ml). The combined organic extracts were washed with saturated brine (50ml), dried over magnesium sulphate and evaporated affording the title compound as a pink oil (0.99g), which was used without further purification.

REFERENCE EXAMPLE 574-Allyloxy-2-fluoro-6-hydroxybenzaldehyde

A mixture of Reference Example 46 (2g), allyl bromide (0.78g), potassium carbonate (0.97g) and potassium iodide (0.14g) in methyl ethyl ketone (100ml) was heated at reflux for 2 hours. The reaction mixture was poured into water (200ml) and extracted three times with diethyl ether (100ml). The combined organic

extracts were washed with saturated brine (200ml), dried over magnesium sulphate and evaporated. The residual brown oil was purified by flash chromatography on silica eluting with a mixture of ethyl acetate and pentane (12:88, v/v). Fractions homogenous in the required product were combined and evaporated affording the title compound (0.92g) as a pale yellow oil.

REFERENCE EXAMPLE 58

10 (RS)-(2-Chlorophenyl)-(1H-tetrazol-5-yl)methanol
A stirred solution of Reference Example 59 (4.26g) in acetonitrile (400ml) and water (50ml) at 5°C was treated with ammonium cerium (IV) nitrate (35g) over 10 minutes. The reaction mixture was allowed to warm to ambient temperature and stirring was continued for 5 hours. The reaction mixture was diluted with dichloromethane (800ml) and washed with water (600ml). The organic phase was dried over magnesium sulphate, evaporated and the residue purified by flash chromatography on silica eluting with a mixture of ethyl acetate and pentane (1:1, v/v). Fractions homogenous in the required product were combined and evaporated affording the title compound (1.33g) as a solid, m.p. 130-132°C. [Elemental analysis:- C,45.93; H,3.35; N,26.0%. Calculated:- C,45.62; H,3.35; N,26.6%].

REFERENCE EXAMPLE 59

30 (RS)-(2-Chlorophenyl)-[1-(4-methoxybenzyl)-1H-tetrazol-5-yl]methanol
A solution of 1-(4-methoxybenzyl)tetrazole (6.12g; Y.Sato and N.Marcopulos, Tetrahedron Letters, 1995, 36, 1759-1762), and N,N,N',N'-tetramethylethylenediamine (10ml) in dry tetrahydrofuran (10ml) under nitrogen was cooled to -95°C and treated dropwise with n-butyl

lithium (2.5M solution in hexanes) over 15 minutes. The reaction mixture was left at -80°C for 15 minutes when 2-chlorobenzaldehyde (4.53g) was added dropwise over 10 minutes maintaining the reaction temperature at or
5 below -80°C. The mixture was stirred at or below -80°C for 30 minutes, allowed to warm to room temperature, quenched with ammonium chloride solution (50ml) and the organic phase separated. The aqueous phase was extracted three times with ethyl acetate (50ml), the
10 combined organics dried over magnesium sulphate and evaporated. The residue was purified by flash chromatography on silica eluting initially with a mixture of ethyl acetate and pentane (1:1, v/v) then with a mixture of ethyl acetate and pentane (2:1, v/v).
15 Fractions homogenous in the required product were combined and evaporated affording the title compound (1.33g) as a white solid, m.p. 128-130°C. [Elemental analysis:- C, 58.22; H, 4.74; N, 17.15%. Calculated:- C, 58.1; H, 4.57; N, 16.94%].

20

REFERENCE EXAMPLE 60

Methyl (RS)[3-chloro-2-cyano-5-(4-pyridylmethoxy)phenoxy]-(2-chlorophenyl)acetate

A mixture of Reference Example 61 (0.15g), 4-
25 picolylchloride hydrochloride (0.15g), potassium carbonate (0.59g), potassium iodide (70mg) and tetra-n-butylammonium bromide (10mg) in methyl ethyl ketone (20ml) was heated at reflux for 1 hour. The reaction mixture was evaporated and partitioned between 10%
30 acetic acid (30ml) and ethyl acetate (30ml). The organic layer was separated and the aqueous layer extracted twice with ethyl acetate (30ml). The combined organic extracts were washed with saturated brine (30ml), dried over magnesium sulphate and evaporated
35 affording the title compound as a pale green gum (0.3g), which was used without further purification.

REFERENCE EXAMPLE 61

Methyl (RS)[3-chloro-2-cyano-5-hydroxyphenoxyl-(2-chlorophenyl)acetate

- 5 Nitrogen was bubbled through a solution of Reference Example 62 (0.66g) in ethanol (20ml) and water (2ml) for 20 minutes. Diazobicyclo[2,2,2]octane (0.021g) and tris(triphenylphosphine)rhodium(I) chloride (61mg) were added and the mixture heated to reflux for 2 hours. The
10 reaction mixture was partitioned between 1N hydrochloric acid (40ml) and ethyl acetate (40ml). The organic layer was separated and the aqueous layer extracted twice with ethyl acetate (40ml). The combined organic extracts were washed with saturated brine
15 (40ml), dried over magnesium sulphate and evaporated. The residual yellow oil was purified by flash chromatography on silica eluting with a mixture of ethyl acetate and petroleum ether (33:67, v/v). Fractions homogenous in the required product were
20 combined and evaporated affording the title compound (0.3g) as a colourless oil.

REFERENCE EXAMPLE 62

Methyl (RS)-[5-allyloxy-3-chloro-2-cyanophenoxy]-(2-chlorophenyl)acetate

- 25 To a solution of Reference Example 63 (0.37g) in dry dimethylformamide (20ml) under a nitrogen atmosphere was added sodium hydride (0.76g, 60% dispersion in mineral oil). The mixture was stirred at room
30 temperature for 20 minutes then treated dropwise with a solution of Reference Example 10 (0.51g) in dry dimethylformamide (5ml). The resulting solution was stirred at room temperature for 1 hour, diluted with water (50ml), acidified to pH 1 by addition of 1N
35 hydrochloric acid and extracted three times with diethyl ether (40ml). The combined organic extracts were washed with saturated brine (40ml), dried over

magnesium sulphate and evaporated. The residual yellow oil was purified by flash chromatography on silica eluting with a mixture of ethyl acetate and petroleum ether (1:4, v/v). Fractions homogenous in the required
5 product were combined and evaporated affording the title compound (0.36g) as a white solid.

REFERENCE EXAMPLE 63

4-Allyloxy-2-chloro-6-hydroxybenzonitrile

A solution of Reference Example 64 (0.63g) in methanol
10 (20ml) and 10% potassium carbonate solution (3ml) was stirred at room temperature for 30 minutes and evaporated to low bulk. The residue was partitioned between water (50ml) and diethyl ether (30ml). The organic layer was separated and discarded. The aqueous
15 layer was acidified to pH 1 by addition of 1N hydrochloric acid and extracted three times with diethyl ether (40ml). The combined organic extracts were washed with saturated brine (30ml), dried over magnesium sulphate and evaporated affording the title
20 compound (0.37g) as a white solid, m.p. 175-176°C.

REFERENCE EXAMPLE 64

2-Acetoxy-4-allyloxy-6-chlorobenzonitrile

A mixture of Reference Example 65 (0.63g), sodium
25 acetate (20mg) and acetic anhydride was heated at reflux for 1.5 hours. The reaction mixture was diluted with water (50ml) and extracted four times with diethyl ether (30ml). The combined organic extracts were washed three times with saturated sodium hydrogen carbonate
30 solution (40ml), with saturated brine (50ml), dried over magnesium sulphate and evaporated affording the title compound as a yellow/brown gum (0.75g) which was used without further purification.

35 REFERENCE EXAMPLE 65

4-Allyloxy-2-chloro-6-hydroxybenzaldehyde oxime

A mixture of Reference Example 66 (0.53g), hydroxylamine hydrochloride (0.17g), pyridine (0.2g) and ethanol (30ml) was stirred at reflux for 1 hour. The mixture was concentrated to low volume and
5 partitioned between water (50ml) and diethyl ether (50ml). The aqueous layer was separated and extracted twice with diethyl ether (50ml). The combined organic extracts were washed with saturated brine (50ml), dried over magnesium sulphate and evaporated affording the
10 title compound as a white solid (0.63g), m.p. 65-66°C, which was used without further purification.

REFERENCE EXAMPLE 66

4-Allyloxy-2-chloro-6-hydroxybenzaldehyde

15 A mixture of Reference Example 67 (3.7g), allyl bromide (1.3g), potassium carbonate (1.5g) and potassium iodide (200mg) in methyl ethyl ketone (100ml) was heated at reflux for 2 hours. The reaction mixture was poured into water (200ml) and extracted three times with
20 diethyl ether (100ml). The combined organic extracts were washed with saturated brine (200ml) and dried over magnesium sulphate and evaporated. The residual brown oil was purified by flash chromatography on silica eluting with a mixture of ethyl acetate and petroleum
25 ether (1:8, v/v). Fractions homogenous in the required product were combined and evaporated affording the title compound (0.53g) as a pale yellow crystalline solid m.p. 35-36°C.

30 REFERENCE EXAMPLE 67

2-Chloro-4,6-dihydroxybenzaldehyde

Pyrophosphonyl chloride (19.49g) was added dropwise to dimethylformamide (10.84ml) over 20 minutes, keeping the temperature at 5°C. To the viscous mixture was
35 added a solution of Reference Example 68 (10.17g) in dimethylformamide (5ml). The mixture was vigorously

stirred at room temperature for 7 hours, and left to stand for another 18 hours. The reaction mixture was neutralised with saturated sodium acetate solution (1000ml) and was then extracted three times with ethyl acetate (400ml). The combined organic extracts were washed with saturated brine (300ml), dried over magnesium sulphate and evaporated. The residual orange oil was purified by flash chromatography on silica eluting with a mixture of methanol and dichloromethane (2:98, v/v). Fractions homogenous in the required product were combined and evaporated affording the title compound (3.7g) as a yellow oil.

REFERENCE EXAMPLE 68

15 5-Chloro-1,3-Dihydroxybenzene

A solution 5-chloro-1,3-dimethoxybenzene (20.71g) in dichloromethane (50ml) at -78°C was treated dropwise with a solution of boron tribromide (56ml) in dichloromethane (250ml), maintaining the temperature at -78°C. The mixture was slowly warmed to room temperature then left at ambient temperature for 48 hours. The reaction mixture was quenched with water (100ml), (sodium hydroxide scrubber required) and partitioned between water (1000ml) and dichloromethane (1000ml). The organic layer was separated and the aqueous layer was extracted twice with a mixture of dichloromethane and methanol (500ml, 98:2, v/v). The combined organic extracts were washed with saturated brine (200ml), dried over magnesium sulphate and evaporated affording the title compound (10.17g) as a yellow/orange oil which was used without further purification.

REFERENCE EXAMPLE 69

35 Methyl (RS)-[5-(benzoxazol-6-ylmethoxy)-2-cyanophenoxy]-(2-methylphenyl)acetate

A mixture of Reference Example 70 (3.24g), Reference Example 48 (2.17g) and potassium carbonate (1.41g) in dry dimethylformamide (60ml) was stirred at room temperature under nitrogen for 18 hours. The reaction mixture was evaporated, water (60ml) was added and the solution extracted three times with ethyl acetate (60ml). The combined extracts were washed twice with water (40ml), then with brine (50ml), dried over magnesium sulphate and evaporated. The residual material was purified by flash chromatography on silica eluting with a mixture of diethyl ether and pentane (1:1, v/v). Fractions homogenous in the required product were combined and evaporated. The residual solid was triturated twice with pentane (10ml) affording the title compound (1.49g) as a white solid, m.p. 157-159°C. [Elemental analysis:- C,64.9; H,3.96; N,6.33; Cl,7.77%. Calculated:- C,64.22; H,3.82; N,6.24; Cl,7.89 %].

20 REFERENCE EXAMPLE 70

Methyl (RS)-(2-cyano-5-hydroxyphenoxy)-(2-methylphenyl)acetate

A stirred solution of Reference Example 71 (17.9g) in methanol (700ml) was treated with 1,4-diazabicyclo(2.2.2)octane (11.9g) and tris(triphenylphosphine)rhodium(I) chloride (2.45g) and refluxed for 1 hour. The reaction mixture was evaporated and the residue treated with 2N hydrochloric acid (400ml). This mixture was extracted four times with ethyl acetate (200ml). The combined extracts were washed with water, then with brine, dried over magnesium sulphate and evaporated. The residual oil was purified by flash chromatography on silica eluting with a mixture of ethyl acetate and pentane (1/1, v/v). Fractions homogenous in the required product were evaporated. The residue was triturated with pentane

affording the title compound (9.5g) as a colourless solid, m.p. 114-121°C. [Elemental analysis:- C,68.7; H,5.06; N,4.51%. Calculated:- C,68.7; H,5.09; N,4.71%].

5 REFERENCE EXAMPLE 71

Methyl (RS)-(5-allyloxy-2-cyanophenoxy)-(2-methylphenyl)acetate

A stirred solution of Reference Example 4 (35.0g) in dry dimethylformamide (350ml) was treated portionwise
10 with sodium hydride (8.0g, 60% dispersion in mineral oil). After stirring at ambient temperature for 30 minutes the mixture was treated with Reference Example 21 (48.6g) and stirring was continued for 24 hours. The reaction mixture was evaporated (45°C/0.1mm) and the
15 residue treated with water (250ml) and extracted three times with ethyl acetate (250ml). The combined extracts were washed with water, dried over magnesium sulphate and evaporated. The residual oil was purified by flash chromatography on silica eluting with dichloromethane.
20 Fractions homogenous in the required product were combined and evaporated. The residue was triturated with pentane affording the title compound (46.6g) as a colourless solid, m.p. 98-99°C. [Elemental analysis:- C,71.2; H,5.71; N,4.07%. Calculated:- C,71.2; H,5.68;
25 N,4.15%].

REFERENCE EXAMPLE 72

(a)(S)-[5-(1,3-Benzodioxol-5-ylmethoxy)-2-cyanophenoxy]-(2-methylphenyl)acetic acid, (-)
30 ephedrine salt

Method A: A solution of Example 19 (0.5g) in diethyl ether (5ml) was treated with a solution of (-) ephedrine (0.2g) in diethyl ether (10ml). After stirring at ambient temperature for 30 minutes the
35 mixture was evaporated and the residue recrystallised twice from a mixture of ethyl acetate and pentane

affording the title compound (0.15g, ee 99.7%) as a white solid, m.p. 171-173°C. [Elemental analysis:- C, 69.92; H, 5.89; N, 4.87%. Calculated:- C, 70.09; H, 5.88; N, 4.81%].

5

Method B: Reference Example 87 (30.0g, 73%ee) was added portionwise (ca 2.5g every 15 minutes) over 3 hours to a stirred, thick white slurry of Reference Example 15 (18.62g) and powdered potassium phosphate (73.42g) in methyl ethyl ketone (200ml) at about 18°C. The reaction mixture was stirred at ambient temperature (about 22°C) for 2.5 hours. Demineralised water (125ml) was added and the pH of the mixture was adjusted to 7 - 7.5 by addition of hydrochloric acid (s.g. 1.18, about 35ml). The aqueous layer was removed then fresh demineralised water (150ml) was added and volatile organics were removed by distillation until the distillate temperature reached 80°C. Ethanol (15ml) was added and distillation was continued until a further 15 ml of distillate had been collected. The residue was heated and ethanol (95ml) was added slowly to bring the reaction mixture to a homogeneous boiling solution, which was then stirred slowly while being allowed to cool. At 55°C seed crystals of the product were added and cooling was gradually continued to 5°C. The product was collected by filtration then washed by resuspending twice in demineralised water (100ml) and dried by suction. The product was suspended in a mixture of ethyl acetate (74ml) and tert-butyl methyl ether (222ml). The mixture was heated under reflux with Dean and Stark azeotropic removal of water for at least 5 hours. The slurry was cooled to about 20°C and filtered. The product was washed with tert-butyl

30

methyl ether (20ml) then dried at about 50°C to give the title compound (21.3g, ee 97.2%).

Method C: A solution of potassium tert-butoxide
5 (137.5g) in tetrahydrofuran (500ml) was added dropwise, over 1 hour, to a stirred suspension of Reference Example 87 (207.1g, ee 78%) and Reference Example 15 (94.27g) in tetrahydrofuran (950ml) maintaining the temperature between 16°C and 19°C. The reaction
10 mixture was then stirred at ambient temperature (ca. 22°C) for 1.5 hours. Demineralised water (1050ml) was added over 5 minutes. The pH of the resulting solution was adjusted to 7 - 7.5 by addition of hydrochloric acid (s.g. 1.18). The mixture was concentrated by
15 distillation until the temperature of the distillate reached about 92°C, then ethanol (200ml) was added. Distillation was continued until the distillate reached about 91°C. Ethanol (600ml) was added to the hot mixture over about 10 minutes to bring the reaction
20 mixture to a homogeneous boiling solution. Heating was discontinued and the solution was stirred slowly while being allowed to cool to 20°C. The product was filtered, washed by being resuspended twice in demineralised water (500ml) and dried by suction. The
25 product was then suspended in a mixture of ethyl acetate (375ml) and tert-butyl methyl ether (1125ml). The mixture was heated under reflux with Dean and Stark azeotropic removal of water for at least 5 hours. The slurry was cooled to about 20°C and filtered. The
30 product was washed with tert-butyl methyl ether (100ml) then dried at about 50°C to give the title compound (107.7g; ee 97.2%).

(b) In a similar manner to method A but replacing Example 19 with Example 42 may be prepared (S)-[5-(1,3-Benzodioxol-5-ylmethoxy)-2-cyano-3-fluorophenoxy]-(2-methylphenyl)acetic acid, (-) ephedrine salt.

5

REFERENCE EXAMPLE 73

Methyl (RS)-[5-(1,3-benzodioxol-5-ylmethoxy)-2-cyanophenoxy]-(2-methylphenyl)acetate

Method A: A mixture of Reference Example 70 (120g),
10 3,4-methylenedioxybenzyl chloride (82.4g) and potassium carbonate (83.8g) in dimethylformamide (650ml) was stirred at room temperature for 1.5 hours then at 50°C for 1.5 hours. The reaction mixture was filtered and the filtrate evaporated. The residue was dissolved in
15 ethyl acetate (500ml), washed twice with 1N sodium hydroxide (150ml), then with brine (150ml), dried over magnesium sulphate and evaporated. The residue was triturated with diethyl ether affording the title compound (135.5g) as a cream coloured solid, m.p. 107-
20 108°C.

Method B: A solution of Reference Example 15 (39.6g) in dimethylformamide (500ml) was treated with sodium hydride (6g, 60% dispersion in mineral oil). After
25 stirring at ambient temperature for 20 minutes the mixture was treated with a solution of Reference Example 21 (39.4g) in dimethylformamide (50ml) and stirring was continued for 3 hours. The reaction mixture was evaporated and partitioned between ethyl
30 acetate (500ml) and water (300ml). The aqueous phase was extracted twice with ethyl acetate (200ml) and the combined organic phases washed with brine (250ml), dried over magnesium sulphate and evaporated. The residue was triturated with diethyl ether affording the

title compound (57.4g) as a white solid, m.p. 112-114°C.

REFERENCE EXAMPLE 74

- 5 Methyl (RS)-[2-cyano-5-(4-(3-fluoropyridyl)methoxy)phenoxy]-(2-methylphenyl)acetate
- A solution of Reference Example 70 (0.26g) in dry dimethylformamide (5ml) was treated with potassium carbonate (0.122g) and the mixture stirred at room
- 10 temperature for 15 minutes. A solution of Reference Example 75 (0.18g) in dry dimethylformamide (1ml) was added and stirring continued for 3 hours. The reaction mixture was diluted with water (100ml) and extracted three times with ethyl acetate (20ml). The combined
- 15 extracts were washed with brine (25ml), dried over magnesium sulphate and evaporated. The residual oil crystallised on standing at room temperature overnight. Trituration with a mixture of dichloromethane and ethyl acetate (4:1, v/v) afforded the title compound (0.05g)
- 20 as a white solid, m.p. 166-167°C. The soluble material was purified by flash chromatography on silica eluting with a mixture of dichloromethane and ethyl acetate (9:1, v/v). Fractions homogenous in the required product were combined and evaporated and the yellow oil
- 25 triturated with pentane affording a further quantity of the title compound (0.1g) as a white solid, m.p. 167-168°C.

REFERENCE EXAMPLE 75

- 30 4-Bromomethyl-2-fluoropyridine
- A solution of 2-fluoro-4-methylpyridine (0.5g) in chloroform (50ml) was treated with N-bromosuccinimide (1.35g) and azobisisobutyronitrile (0.25g). The mixture was heated at reflux for 30 hours, cooled to room
- 35 temperature and washed with water (30ml). The

chloroform solution was evaporated and the resulting brown oil purified by flash chromatography on silica eluting initially with a mixture of ethyl acetate and pentane (1:9, v/v) then with a mixture of ethyl acetate and pentane (15:85, v/v). Fractions homogenous in the required product were combined and evaporated affording the title compound (0.18g) as a yellow oil.

REFERENCE EXAMPLE 76

10 (RS)-(2-Methylphenyl)-(1H-tetrazol-5-yl)methanol

A solution of Reference Example 77 (9.27g) in acetonitrile (250ml) and water (40ml) cooled in an ice-bath was treated portionwise over 10 minutes with ammonium cerium (IV) nitrate (82.2g). The reaction mixture was warmed to room temperature and stirred for 2.5 hours. The mixture was diluted with dichloromethane (800ml) and washed with water (400ml). The organic phase was dried over magnesium sulphate and evaporated. The residue was purified by flash chromatography on silica eluting with a mixture of ethyl acetate and pentane (1:1, v/v). Fractions homogenous in the required product were combined and evaporated affording the title compound (4.8g) as a cream solid, m.p. 124-126°C.

25

REFERENCE EXAMPLE 77

(RS)-[1-(4-Methoxybenzyl)-1H-tetrazol-5-yl]-(2-methylphenyl)methanol

A stirred solution of 1-(4-methoxybenzyl)tetrazole (7.04g, Tetrahedron Letters, 1995, p1759-1762) in a mixture of dry tetrahydrofuran (120ml) and N,N,N',N',-tetramethylethylenediamine (12ml) under a nitrogen atmosphere at -85°C was treated dropwise with n-butyl lithium (18ml, 2.5M solution in hexanes) over 10 minutes. After stirring at -85°C for an additional 5

minutes a solution of o-tolualdehyde (4.45g) in dry tetrahydrofuran (20ml) was added dropwise over 10 minutes. The reaction mixture was stirred at -85°C for 30 minutes, allowed to warm to room temperature, then
5 quenched with saturated ammonium chloride solution (50ml). The organic phase was separated and the aqueous phase extracted three times with ethyl acetate (100ml). The combined organic phases were dried over magnesium sulphate and evaporated. The residue was purified by
10 flash chromatography on silica eluting initially with a mixture of ethyl acetate and pentane (1:1, v/v) then with a mixture of ethyl acetate and pentane (66:34, v/v). Fractions homogenous in the required product were combined and evaporated affording the title compound
15 (9.8g) as a white solid, m.p. 90-92°C. [Elemental analysis:- C, 65.91, H, 5.9, N, 18.1%. Calculated:- C, 65.79, H, 5.85, N, 18.05%].

REFERENCE EXAMPLE 78

20 Methyl (RS)-[2-cyano-3-fluoro-5-(4-pyridylmethoxy)phenoxy]-(2-methylphenyl)acetate
A mixture of Reference Example 79 (0.5g), 4-picolylchloride hydrochloride (0.29g), potassium carbonate (1.11g), potassium iodide (130mg) and tetra-
25 n-butylammonium bromide (20mg) in methyl ethyl ketone (30ml) was heated at reflux for 1 hour. The mixture was evaporated to dryness and partitioned between 10% acetic acid (50ml) and ethyl acetate (50ml). The organic phase was separated and the aqueous layer
30 extracted twice with ethyl acetate (50ml). The combined organic phases were washed with saturated brine (50ml), dried over magnesium sulphate and evaporated affording the title compound (0.64g) as a yellow oil, which was used without further purification.

REFERENCE EXAMPLE 79

Methyl (RS)-[2-cyano-3-fluoro-5-hydroxyphenoxy]-(2-methylphenyl)acetate

Nitrogen was bubbled through a solution of Reference
5 Example 80 (3.1g) in a mixture of ethanol (100ml) and
water (10ml) for 20 minutes. The solution was treated
with 1,4-diazabicyclo[2.2.2]octane (0.2g) and
tris(triphenylphosphine)rhodium(I) chloride (610mg) and
10 heated at reflux for 4.5 hours. The reaction mixture
was cooled to room temperature and partitioned between
1N hydrochloric acid (50ml) and ethyl acetate (50ml).
The organic phase was separated and the aqueous layer
extracted three times with ethyl acetate (50ml). The
combined organic phases were washed with saturated
15 brine (50ml), dried over magnesium sulphate and
evaporated affording the title compound (3.7g) as a
yellow gum which was used without further purification.

REFERENCE EXAMPLE 80

20 Methyl (RS)-[5-allyloxy-2-cyano-3-fluorophenoxy]-(2-methylphenyl)acetate

A stirred solution of Reference Example 54 (3.0g) in
dry dimethylformamide (90ml), under a nitrogen
atmosphere was treated with sodium hydride (0.68g, 60%
25 dispersion in mineral oil). After stirring at ambient
temperature for 20 minutes a solution of Reference
Example 21 (4.15g) in dry dimethylformamide (10ml) was
added dropwise. The resulting solution was stirred at
room temperature for 3 hour then quenched with water
30 (200ml). The solution was acidified to pH 1 by addition
of 1N hydrochloric acid and extracted five times with
diethyl ether (50ml). The combined extracts were washed
with saturated brine (50ml), dried over magnesium
sulphate and evaporated. The residual red oil was
35 purified by flash chromatography on silica eluting with
a mixture of ethyl acetate and petroleum ether (1:5,
v/v). Fractions homogenous in the required product were

combined and evaporated affording the title compound (3.1g) as a white solid, m.p. 100-102°C.

REFERENCE EXAMPLE 81

5 Methyl (RS)-[5-(benzoxazol-6-ylmethoxy)-2-cyano-3-fluorophenoxy]-(2-methylphenyl)acetate

A mixture of Reference Example 79 (0.5g), Reference Example 48 (0.37g), potassium carbonate (1.11g), potassium iodide (130mg) and tetra-n-butylammonium
10 bromide (20mg) in methyl ethyl ketone (30ml) was heated at reflux for 1 hour. The reaction mixture was evaporated to dryness and partitioned between water (50ml) and ethyl acetate (50ml). The organic phase was separated and the aqueous layer extracted twice with
15 ethyl acetate (50ml). The combined organic extracts were washed with saturated brine (50ml), dried over magnesium sulphate and evaporated. The residual colourless gum was purified by flash chromatography on silica eluting with a mixture of ethyl acetate and
20 pentane (66:34, v/v). Fractions homogenous in the required product were combined and evaporated affording the title compound (0.35g) as a colourless gum.

REFERENCE EXAMPLE 82

25 Methyl (RS)-[5-(1,3-benzodioxol-5-ylmethoxy)-2-cyano-3-fluorophenoxy]-(2-methylphenyl)acetate

A mixture of Reference Example 79 (0.5g), 3,4-methylenedioxybenzyl chloride (0.30g), potassium carbonate (1.11g), potassium iodide (130mg) and tetra-
30 n-butylammonium bromide (20mg) in methyl ethyl ketone (30ml) was heated at reflux for 1 hour. The reaction mixture was evaporated and the residue partitioned between water (50ml) and ethyl acetate (50ml). The organic phase was separated and the aqueous layer
35 extracted twice with ethyl acetate (50ml). The combined organic extracts were washed with saturated brine

(50ml), dried over magnesium sulphate and evaporated affording the title compound as a brown oil (0.66g), which was used without further purification.

5 REFERENCE EXAMPLE 83

Methyl (RS)-[5-(benzoxazol-5-yl)methoxy-2-cyanophenoxy]-(2-methylphenyl)acetate

A mixture of Reference Example 70 (0.50g), Reference Example 84 (0.35g), potassium carbonate (0.23g), and
10 dimethylformamide (10ml) was stirred at room temperature for 1.5 hours. The reaction mixture was concentrated, diluted with water (30ml), and extracted twice with ethyl acetate (50ml). The combined extracts were washed twice with 1N aqueous
15 sodium hydroxide (20ml), then with brine (20ml), dried over magnesium sulphate and evaporated. The resulting residue was purified by flash chromatography on silica eluting with a mixture of ethyl acetate and pentane (1:4, v/v). Fractions
20 homogenous in the required product were combined and evaporated to afford the title compound (0.12g) as a colourless oil.

REFERENCE EXAMPLE 84

25 5-Bromomethylbenzoxazole

A solution of 5-methylbenzoxazole (0.5g) in chloroform (20ml) containing N-bromosuccinimide (0.18g) and azoisobutyronitrile (0.05g) was refluxed
for 2 hours. After allowing to cool to room
30 temperature the reaction mixture was treated with water (30ml). The organic phase was separated and the aqueous phase extracted with dichloromethane (30ml). The combined organic phases were washed with brine (30ml), dried over magnesium sulphate and evaporated.
35 The residue was triturated with pentane giving the

title compound (0.36g) as an off-white solid, m.p. 90-93°C.

REFERENCE EXAMPLE 85

5 Methyl (RS)-(5-benzyloxy-2-cyanophenoxy)-(2-methylphenyl)acetate

A mixture of Reference Example 70 (0.50g), benzyl chloride (0.24ml), potassium carbonate (0.28g), and dimethylformamide (10ml) was stirred at room
10 temperature. After 18 hours the reaction mixture was diluted with water (30ml) and extracted twice with ethyl acetate (50ml). The combined organic extracts were washed twice with 1N aqueous sodium hydroxide (20ml), then with brine (20ml), dried over magnesium
15 sulphate and evaporated. The residue was triturated with a mixture of pentane and ethyl acetate giving the title compound (0.49g) as a white solid, m.p. 134-136°C.

20 REFERENCE EXAMPLE 86

Methyl (RS)-[2-cyano-5-(furan-3-ylmethoxy)phenoxy]-(2-methylphenyl)acetate

A stirred solution of triphenylphosphine (1.04g) in tetrahydrofuran (30ml) was treated with diisopropyl
25 azodicarboxylate (0.78g) at 0°C. The resulting suspension was stirred for 20 minutes, then treated with a solution of Reference Example 70 (1.19g) and furan-3-methanol (0.39g) in tetrahydrofuran (20ml). After stirring at room temperature for 2 hours the
30 solution was evaporated and the residue dissolved in ether (80ml). The solution was washed twice with water (20ml), dried over magnesium sulphate and evaporated. The resulting residue was purified by flash chromatography on silica eluting with a mixture
35 of pentane and ether (3:2, v/v). Fractions

homogenous in the required product were combined and evaporated to afford the title compound (1.3g) as a colourless solid, shown by ¹HMR to be contaminated with diisopropylhydrazine dicarboxylate.

5

REFERENCE EXAMPLE 87

α -Bromo-(2-methylphenyl)acetic acid, (-)-ephedrine salt

10 A solution of (-)-ephedrine (27.17g) in ethyl acetate (198ml) was added dropwise over 3 hours to a stirred solution of α -bromo-(2-methylphenyl)acetic acid (39.7g) and tetra-n-butylammonium bromide (5.75g) in ethyl acetate (278ml) keeping the temperature between 20°C and 23°C. The resulting suspension was stirred

15 at 20-23°C for 2 hours and filtered. Some of the filtrate (300-350ml) was used to aid transfer of the reaction mixture to the filter. The product was washed twice with ethyl acetate (100ml), then washed three times with tert-butyl methyl ether (100ml) and

20 dried at 35-40°C / 40-50 torr to give the title compound (47.2g), ee 78% (for α -bromo-(2-methylphenyl)acetic acid) was determined by chiral HPLC using a Chiralpak AS column (Diacel) and a mobile phase of heptane/isopropanol/trifluoroacetic

25 acid (960/40/2, by volume), with UV detection at 254nm.

30 IN VITRO TESTS

A) Preparation of ETA receptors:

A10 cells are grown to confluence in Dulbecco's modified essential medium containing 10% foetal calf serum. Two days after the final medium change cells are harvested by scraping from the base of the flask and centrifuged at 1500 rpm for 10 minutes at 4°C in a bench centrifuge. The resulting pellets are washed in 50mM Hepes buffer pH 7.3 containing calcium chloride (1mM) and magnesium chloride (5mM) and resuspended at a density of 140,000 cells/ml in the same. Cell suspensions are then frozen using a mixture of methanol and solid carbon dioxide and stored at -20°C until required. For use in the assay cells are diluted to the required density with Hepes buffer pH 7.3.

15

B) Preparation of ET_B receptors:

Rats are killed by cervical dislocation and the cerebellum tissue is removed into ice cold Tris buffer pH 7.4 containing sucrose (0.25M), ethylenediaminetetracetic acid (3mM), and a cocktail of protease inhibitors. After homogenizing using a glass/teflon manual homogenizer, the samples are centrifuged at 4°C for 17 minutes at 1000g, and the resulting supernatants are retained. This material is centrifuged at 4000g for 35 minutes at 4°C and the pellets are resuspended in 50mM Tris buffer pH 7.4, and the protein concentration is measured. Aliquots of 100ml are frozen in a mixture of methanol and solid carbon dioxide and stored at -20°C until required. For use in the assay samples are diluted to the required concentration with Tris buffer pH 7.4 containing 0.1% bovine serum albumin.

35 C) Assay methodology:

Assays are performed using Millipore 96 well filtration plates with 0.22 μ m filters in a final volume of 250ml. Mixtures consisting of test compound and [125 I]-ET-1 (20pM) in buffer pH 7.4 containing 0.1% bovine serum albumin are treated with either A10 cells or cerebellum protein. Total and non-specific binding are measured in the absence and presence of unlabelled ET-1 (100nM). Approximately 60,000 A10 cells are used per well or 5 μ g of cerebellum protein. Plates are incubated for 2 hours at 37°C before the reaction is terminated by vacuum filtration. Plates are washed twice with assay buffer at 4°C and the filters are punched out for gamma counting.

15 D) Results:

Compounds within the scope of the invention produce 50% inhibition of the binding of [125 I]-ET-1 to A10 cell ET_A receptors at concentrations from about 10⁻⁹M up to about 10⁻⁶M, preferably from about 10⁻⁹M up to about 10⁻⁸M. The compounds of the invention are from about 19,000-fold to about 50-fold more selective for ET_A receptors than ET_B receptors

25


IN VIVO TESTS

The dose-dependent effect of ET_A antagonists was assessed on the ET-1 mediated pressor response in the presence of BQ 788 in the pithed rat. Male Sprague Dawley rats (250-350g) were anaesthetised with isoflurane, pithed and artificially respired. The jugular vein and carotid artery were cannulated for administration of vehicle or test compound and measurement of blood pressure and heart rate. BQ 788 (3mg/kg) and compounds at 25 μ mol/kg were given i.v.

10 min prior to ET-1 cumulative dose response curve
(0.01-10nmol/kg). In the pithed rat compounds of
this invention caused rightward, parallel dose-
dependent shifts from vehicle control. The shift from
5 vehicle for each ET antagonist was calculated using
the dose of ET-1 which caused a 40mm Hg change in
diastolic blood pressure. The range in shifts
produced by compounds within the scope of this
invention at 25 μ mol/kg i.v. were from 3 to 80 fold
10 with the preferred activity being closer to 80 fold.

CLAIMS

1. A compound of formula (I):



wherein

R^1 is CN, CH_2CN , $CH=CHCN$, CHO, or $CH=CHCO_2H$;

10 R^2 is aryl lower alkoxy, heteroaryl lower alkoxy, aryl lower alkylthio or heteroaryl lower alkylthio in which each of the aryl and heteroaryl moieties is optionally substituted;

R^3 is halogen;

15 R^4 is optionally substituted aryl or optionally substituted heteroaryl;

R^5 is carboxy or an acid isostere;

X is oxygen or sulphur; and


20 n is zero or 1; and their N-oxides and prodrugs, and pharmaceutically acceptable salts thereof.

2. A compound according to Claim 1 in which R^1 is attached at the ring 2-position.

25 3. A compound according to Claim 1 or 2 in which R^2 is attached at the ring 5-position.

4. A compound according to any preceding claim in which R^3 is attached at the ring 3-position.

5. A compound of formula (1a)



wherein R¹, R², R³, R⁴, R⁵, n and X are as defined in
5 Claim 1, and their N-oxides and prodrugs, and
pharmaceutically acceptable salts thereof.

6. A compound according to any preceding claim in which
10 R¹ is CN.

7. A compound according to any preceding claim in which
R² is heteroaryl lower alkoxy.

8. A compound according to Claim 7 in which R² is
15 heteroarylmethoxy.


9. A compound according to any preceding claim in which
R⁴ is optionally substituted aryl.

20 10. A compound according to any preceding claim in
which R⁵ is carboxy.

11. A compound according to any preceding claim in
which X is oxygen.

25

12. A compound of formula (Ib)



wherein R^2 , R^3 , R^4 and n are as defined in any relevant preceding claim, and their N-oxides and prodrugs, and pharmaceutically acceptable salts thereof.

5

13. A compound according to any preceding claim in which R^2 is pyridylmethoxy, pyridazinylmethoxy, thienylmethoxy, isothiazolylmethoxy or 1,3-benzodioxolylmethoxy.

10

14. A compound according to any preceding claim in which R^3 is a fluorine atom.

15. A compound according to any preceding claim in

15

which R^4 is phenyl substituted in the ortho position relative to the attachment of the phenyl group to the rest of the R^4 moiety by lower alkyl, CF_3 or chlorine and is optionally further substituted by one or more of halogen, lower alkyl, CN or lower alkoxy.

20

16. A compound according to any preceding claim in which the chiral centre associated with the carbon atom α to the moiety X within the group $-X-CHR^4R^5$, or the carbon atom α to the oxygen atom within the group

25

$-O-CHR^4CO_2H$, has the (S) configuration.

17. A compound selected from :

- (RS)-(2-chlorophenyl)-[2-cyano-5-(4-pyridylmethoxy)-phenoxy]acetic acid;
(RS)-[2-cyano-5-(3-thienylmethoxy)phenoxy]-phenylacetic acid;
5 (RS)-(2-chlorophenyl)-[2-cyano-5-(3-thienylmethoxy)-phenoxy]acetic acid;
(RS)-[5-(1,3-benzodioxol-5-ylmethoxy)-2-cyanophenoxy]-phenylacetic acid;
(RS)-[5-(1,3-benzodioxol-5-ylmethoxy)-2-cyanophenoxy]-
10 (2-trifluoromethylphenyl)acetic acid;
(RS)-[2-cyano-5-(3-thienylmethoxy)phenoxy]-(2-methylphenyl)acetic acid;
(RS)-[5-(1,3-benzodioxol-5-ylmethoxy)-2-cyanophenoxy]-(2-chlorophenyl)acetic acid;
15 (RS)-(2-bromophenyl)-[2-cyano-5-(3-thienylmethoxy)-phenoxy]acetic acid;
(RS)-(3-chlorophenyl)-[2-cyano-5-(3-thienylmethoxy)-phenoxy]acetic acid;
(R)-(2-chlorophenyl)-[2-cyano-5-(3-thienylmethoxy)-
20 phenoxy]acetic acid;
(S)-(2-chlorophenyl)-[2-cyano-5-(3-thienylmethoxy)-phenoxy]acetic acid;
(RS)-[2-cyano-5-(4-pyridylmethoxy)phenoxy]-phenylacetic acid;
25 (RS)-[2-cyano-5-(3-thienylmethoxy)phenoxy]-(2-fluorophenyl)acetic acid;
(RS)-[2-cyano-5-(4-pyridylmethoxy)phenoxy]-(2-methylphenyl)acetic acid;
(RS)-[2-cyano-5-(3-thienylmethoxy)phenoxy]-(2-
30 trifluoromethylphenyl)acetic acid;
(RS)-(2-bromophenyl)-[2-cyano-5-(4-pyridylmethoxy)-phenoxy]acetic acid;
(RS)-[2-cyano-5-(4-pyridylmethoxy)phenoxy]-(2-trifluoromethylphenyl)acetic acid;
35 (S)-[2-cyano-5-(4-pyridylmethoxy)phenoxy]-(2-methylphenyl)acetic acid;

- (RS)-(2-chlorophenyl)-[2-cyano-5-(pyridazin-4-yl-methoxy)phenoxy]acetic acid;
(RS)-[5-(1,3-benzodioxol-5-ylmethoxy)-2-cyanophenoxy]-(2-methylphenyl)acetic acid;
5 (RS)-(2-chlorophenyl)-[2-cyano-5-(isothiazol-4-ylmethoxy)phenoxy]acetic acid;
(RS)-[2-cyano-5-(3-pyridylmethoxy)phenoxy]phenyl-acetic acid;
(RS)-[2-formyl-5-(3-thienylmethoxy)phenoxy]phenyl-
10 acetic acid;
(RS)-N-([2-cyano-5-(3-thienylmethoxy)phenoxy]-phenylacetyl)-4-isopropylbenzenesulphonamide;
(RS)-[2-cyano-5-(4-pyridylmethoxy)phenoxy]-(2-methylphenyl)acetic acid, acetoxymethyl ester;
15 (RS)-(2-chlorophenyl)-[2-cyano-3-fluoro-5-(3-thienylmethoxy)phenoxy]acetic acid;
(RS)-[5-(benzoxazol-6-ylmethoxy)-2-cyanophenoxy]-(2-chlorophenyl)acetic acid;
(RS)-[2-cyano-5-(4-pyridylmethoxy)phenoxy]-[2-(3-methyl)thienyl]acetic acid;
20 (RS)-[(2-cyano-5-(thiazol-5-ylmethoxy)phenoxy]-(2-methylphenyl)acetic acid;
(RS)-(2-chlorophenyl)-[2-cyano-3-fluoro-5-(4-pyridylmethoxy)phenoxy]acetic acid;
25 (RS)-2-[(2-chlorophenyl)-(1H-tetrazol-5-yl)methoxy]-4-(4-pyridylmethoxy)benzonitrile;
(RS)-[3-chloro-2-cyano-5-(4-pyridylmethoxy)phenoxy]-(2-chlorophenyl)acetic acid;
(RS)-[5-(benzoxazol-6-ylmethoxy)-2-cyanophenoxy]-(2-methylphenyl)acetic acid;
30 (S)-[5-(1,3-benzodioxol-5-ylmethoxy)-2-cyanophenoxy]-(2-methylphenyl)acetic acid;
(S)-[5-(1,3-benzodioxol-5-ylmethoxy)-2-cyano-3-fluorophenoxy]-(2-methylphenyl)acetic acid;
35 (RS)-[2-cyano-5-(4-(3-fluoropyridyl)methoxy)phenoxy]-(2-methylphenyl)acetic acid;

- (RS)-2-[(2-methylphenyl)-(1H-tetrazol-5-yl)methoxy]-4-(4-pyridylmethoxy)benzonitrile;
(RS)-4-(1,3-benzodioxol-5-ylmethoxy)-2-[(2-methylphenyl)-(1H-tetrazol-5-yl)methoxy]benzonitrile;
5 (RS)-[2-cyano-3-fluoro-5-(4-pyridylmethoxy)phenoxy]-(2-methylphenyl)acetic acid;
(RS)-[5-(benzoxazol-6-ylmethoxy)-2-cyano-3-fluorophenoxy]-(2-methylphenyl)acetic acid;
(RS)-[5-(1,3-benzodioxol-5-ylmethoxy)-2-cyano-3-fluorophenoxy]-(2-methylphenyl)acetic acid;
10 (RS)-[5-(benzoxazol-5-yl)methoxy-2-cyanophenoxy]-(2-methylphenyl)acetic acid;
(RS)-(5-benzyloxy-2-cyanophenoxy)-(2-methylphenyl)acetic acid;
15 (RS)-[2-cyano-5-(furan-3-ylmethoxy)phenoxy]-(2-methylphenyl)acetic acid;
(RS)-N-methoxy-[2-cyano-5-(3-thienylmethoxy)phenoxy]-(2-methylphenyl)acetamide; and solvates (e.g. hydrates); and pharmaceutically acceptable salts
20 thereof.

18. A compound selected from :

- (RS)-(2-chlorophenyl)-[2-cyano-5-(4-pyridylmethoxy)phenoxy]acetic acid;
25 (S)-[5-(1,3-benzodioxol-5-ylmethoxy)-2-cyanophenoxy]-(2-methylphenyl)acetic acid;
(RS)-[5-(1,3-benzodioxol-5-ylmethoxy)-2-cyanophenoxy]-(2-methylphenyl)acetic acid;
30 (RS)-[2-cyano-5-(4-pyridylmethoxy)phenoxy]-(2-methylphenyl)acetic acid;
(S)-[2-cyano-5-(4-pyridylmethoxy)phenoxy]-(2-methylphenyl)acetic acid;
(RS)-[5-(1,3-benzodioxol-5-ylmethoxy)-2-cyano-3-fluorophenoxy]-(2-methylphenyl)acetic acid;
35 (S)-[5-(1,3-benzodioxol-5-ylmethoxy)-2-cyano-3-fluorophenoxy]-(2-methylphenyl)acetic acid; and

solvates (e.g. hydrates); and pharmaceutically acceptable salts thereof.

5 19. (S)-[5-(1,3-Benzodioxol-5-ylmethoxy)-2-cyano-phenoxy]-(2-methylphenyl)acetic acid; and solvates (e.g. hydrates); and pharmaceutically acceptable salts thereof.

10 20. A pharmaceutical composition comprising a compound according to Claim 1 together with a pharmaceutically acceptable carrier or excipient.

15 21. A pharmaceutical composition for use in the treatment of a disease state associated with a physiological detrimental excess of endothelin or a disease state associated with pathological conditions that are modulated by inhibiting endothelin comprising an effective amount of the compound according to Claim 1.

20 22. A compound according to Claim 1 for use in therapy.


25 23. The use of a compound according to Claim 1 for the manufacture of a medicament for the treatment of a disease state associated with a physiological detrimental excess of endothelin or a disease state associated with pathological conditions that are modulated by inhibiting endothelin.

30 24. The use of a compound according to Claim 1 in combination therapy with one or more of endothelin converting enzyme inhibitors, angiotensin II receptor antagonists, renin inhibitors, angiotensin converting enzyme inhibitors, α - and β -adrenoceptor agonists and antagonists, diuretics, potassium channel activators, calcium channel antagonists, nitrates, antiarrhythmic


agents, positive inotropic agents, serotonin receptor agonists and antagonists, platelet activating factor antagonists, histamine receptor antagonists, proton pump inhibitors, antithrombotic and thrombolytic agents, lipid lowering agents, antibiotic agents and phosphodiesterase inhibitors for the treatment of a disease state associated with a physiological detrimental excess of endothelin or a disease state associated with pathological conditions that are modulated by inhibiting endothelin.

25. A process for the preparation of a compound of formula (1) as claimed in claim 1 which comprises :

(A) reacting a compound of formula (II)




with a compound of formula (III)



wherein Y is a leaving group such as a halogen atom or an aryl- or alkyl-sulphonyloxy group (e.g. methane- or p-toluene-sulphonyloxy) and R^{5a} is a protected derivative of R^5 , including carboxylic acid ammonium salts, followed by removal of the protecting group; or


123

(B) where R^1 is CN attached at the ring 2-position,
 reacting a compound of formula (IV)



5


with a compound of formula (V)



10 or a corresponding thiol; or

(C) where X is oxygen and R^2 is aryl lower alkoxy or
 heteroaryl lower alkoxy, treating a compound of formula
 (VI)

15



wherein R^{5a} is a protected derivative of R^5 , with an
 20 arylalkyl or heteroarylalkyl halide in the presence of
 a suitable base, followed where necessary by removing
 any protecting groups present;

with salt and prodrug formation, and conversion of R⁵ to a carboxylic acid isostere as optional subsequent steps.

- 5 26. A method for treating a disease state capable of being ameliorated by the administration of an inhibitor of endothelin comprising administering to a patient suffering from said disease state an effective amount of a compound of claim 1.

10

27. A compound substantially as hereinbefore described with reference to the Examples.

INTERNATIONAL SEARCH REPORT

International Application No
PC/GB 96/00120

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D213/30 A61K31/19 A61K31/41 A61K31/44 C07D333/16
C07D317/54 C07C59/70

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| A | EP,A,0 617 001 (MERCK & CO INC) 28 September 1994 see the whole document ----- | 1-27 |

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- * "A" document defining the general state of the art which is not considered to be of particular relevance
- * "E" earlier document but published on or after the international filing date
- * "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- * "O" document referring to an oral disclosure, use, exhibition or other means
- * "P" document published prior to the international filing date but later than the priority date claimed

- * "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- * "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- * "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * "A" document member of the same patent family

Date of the actual completion of the international search

13 May 1996

Date of mailing of the international search report

23.05.1996

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

De Jong, B

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/GB 96/00120

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|----------------------------|---------------------|
| EP-A-0617001 | 28-09-94 | AU-B- 5787894 | 22-09-94 |
| | | CA-A- 2119051 | 20-09-94 |
| | | CZ-A- 9502335 | 17-01-96 |
| | | FI-A- 954404 | 18-09-95 |
| | | NO-A- 953672 | 17-11-95 |
| | | PL-A- 310661 | 27-12-95 |
| | | WO-A- 9421590 | 29-09-94 |
| | | ZA-A- 9401923 | 14-10-94 |
| ----- | | | |